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Prostate cancer (PCa) is the second leading cause of cancer-related deaths in men in the 
United States, with most deaths occurring from bone metastasis. Several new therapies have 
been FDA approved for bone-metastatic PCa, but patient survival has only marginally 
improved due to therapy resistance, which often arises from constitutive activation of 
compensatory signaling pathways. This dissertation work focused on a mechanistic 
understanding of how cross talk between tyrosine kinase receptors contributes to therapy 
resistance, and how this may be overcome by downregulating expression of these receptors. 
In PCa cell lines and xenograft models, I demonstrated that activation of IGF-1R receptor 
tyrosine kinase (RTK) through IGF-1 leads to delayed, ligand-independent activation of 
another RTK, MET, that requires Src activation and transcription, suggesting that 
downregulation of expression of these kinases may be required for better inhibition of their 
functions.  
I therefore examined the biologic effects of overexpression of miR-34a, a tumor suppressive 
microRNA that downregulates multiple proteins involved in PCa progression. I demonstrated 
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that miR-34a is downregulated in high metastatic PCa cell lines, concomitant with its targets 
being overexpressed. Overexpression of miR-34a decreased several properties associated 
with metastasis, including-migration, invasion, and proliferation. I next demonstrated that 
miR-34a delivery to xenografts grown in the femurs of immunocompromised mice inhibited 
prostate tumor growth and preserved bone integrity.  
To examine the mechanisms by which miR-34a overexpression inhibited cancer growth, 
autophagy and apoptosis pathways were studied. I determined the expression of autophagy 
markers and the requirement of key signaling intermediates in the autophagic pathway upon 
miR-34a overexpression. I demonstrated that miR-34a overexpression induced apoptosis 
along with a non-canonical form of autophagy that is independent of ATG5, ATG7 and 
Beclin-1 expression. 
In summary, studies in this dissertation provide evidence for IGF-1/1R induced ligand-
independent MET activation, suggesting that cross talk among receptors may be responsible 
for resistance to targeted therapies. To potentially overcome this problem, I demonstrated 
that delivery of miR-34a that downregulates proteins involved in PCa progression decreases 
tumor growth in the bone. Overexpression of miR-34a induces apoptosis and a novel form of 
autophagy that might contribute to its therapeutic effects. 
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Chapter 1 
Introduction 
  
 
 
1 
Overview of Prostate Cancer 
Prostate cancer (PCa) is the second most prevalent cancer in men in the United States 
[1, 2]. It is estimated that in 2014 there will be 233,000 new cases and 29,480 deaths will 
occur from PCa [1]. Improvements in diagnostic methods that aid in early detection and 
successful surgical intervention and/or radiation therapy have led to nearly 100% five-year 
survival rate for patients with localized tumor [1, 2]. However, five-year survival rates drops 
to 28% with the development of distant metastasis [1], which is most common in the bone, 
followed by lungs, liver and brain [3]. Bone metastasis contributes to 90% of the deaths from 
PCa due to lack of effective treatment approaches [4]. Early stage prostate cancer cells are 
dependent on androgens for their survival and proliferation and androgen-ablation therapies 
are effective treatment modalities at this stage. However, most patients with advanced stage 
cancer develop progressive disease even with castrate levels of androgens leading to 
metastatic castrate-resistant prostate cancer (mCRPC) [5].  
Increasing age is the only well-established risk factor for PCa with 60% of the cases 
being diagnosed in men 65 years of age and older [2]. Other risk factors associated with PCa 
include, family history, inherited genetic conditions (such as Lynch syndrome and BRAC2 
mutation), obesity, high diary and processed meat diet, and African ancestry [2, 6]. Some of 
these risk factors might contribute to higher incidence rates for prostate cancer in African 
American men than in non-Hispanic white men [2]. Thus, it is important to better understand 
the genetic, epigenetic and molecular alterations in progressive PCa as well as the tumor 
microenvironment interactions that promote cancer survival and progression for development 
of successful treatment modalities for advanced disease. 
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Pathology of Prostate Cancer 
The prostate gland is a part of male reproductive system responsible for producing 
and storing one third of the seminal fluid. Adult prostate is an acorn-shaped gland, located 
below the bladder comprising of three cell types: luminal, basal and neuroendocrine cells. 
Luminal cells, the major constituents of the gland, carry out secretory functions, express low-
molecular weight cytokeratins (CK8/18), express androgen receptor and are dependent on 
androgen signaling [6, 7]. Androgens are required for normal prostate function as they bind 
to androgen receptor (AR) that then translocates to the nucleus and control transcriptional 
expression of androgen-regulated genes that are required for production of seminal fluids [8]. 
The basal cells are aligned between luminal cells and the basement membrane and thought to 
serve as a barrier to protect luminal cells from oncogenic insults. It has been speculated that 
basal cell layer has stem cell functions and basal cells can differentiate into luminal cells to 
give rise to prostatic carcinomas [6, 7]. Basal cells express high-molecular weight 
cytokeratins (CK5/14) and are not dependent on androgen signaling [6, 7]. Neuroendocrine 
cells express synaptophysin and chromagranin A and constitute a very small fraction of the 
prostate cells and are involved in secreting serotonin and other neuropeptides [9].  
The cell of origin of prostate cancer is controversial with Okada et al. reporting 
majority of prostate adenocarcinoma with luminal cytokeratin marker staining, suggesting 
luminal cells as the origin of PCa [10]. However, cancer recurrence after anti-hormonal 
therapy and progression of metastatic castrate resistant prostate cancer (mCRPC) suggest 
androgen independent basal cells as the cell of origin [7]. Furthermore, Verhagen et al. 
identified an intermediate cell population with basal and luminal markers in the primary PCa 
and hormone-independent PCa [11] and upregulation of prostate stem cell antigen (PSCA), a 
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marker for intermediate cells in prostate cancer suggests intermediate cells as the cell of 
origin [7]. The work of Choi, et al. identified that both luminal and basal cell population have 
self-renewal abilities leading to cancer initiation in a Pten-null mouse model further 
demonstrating that basal cells are capable of differentiating into luminal cells and suggesting 
the role of basal-luminal differentiation for prostate cancer initiation [12].  
McNeal, et al. in their seminal paper defined three distinct morphological regions in the 
human prostate, which are the peripheral zone, the transition zone and the central zone [13].  
The non-malignant Benign Prostatic Hyperplasia (BPH) occurs mostly in the transition zone 
while prostate carcinoma occurs mainly in the peripheral zone [13, 14].  
Prostate cancer is pathologically classified by morphological criteria based on sum of 
Gleason score and clinically by TNM staging. The Gleason grading system takes into 
account appearance of the architecture of prostate cancer cells under the microscope and 
assigns primary and secondary Gleason grades to the most prevalent and second most 
prevalent pattern of the tumor specimen [15]. The Gleason grades range from 1 to 5, and 
Gleason score is determined by the sum of primary and secondary grade. The Gleason scores 
thus, range from 2 to10, with higher score indicative of poorly differentiated cells and more 
advanced cancer. A Gleason score of 8-10 has higher risk of cancer recurrence, metastasis 
and death [16]. In addition to the morphology of the cells, the TNM staging system, which 
evaluates the size and range of the primary tumor (T), the involvement of lymph nodes (N) 
and the degree of distant metastasis (M) is also widely used by clinicians to predict survival 
and prognosis with higher staging indicative advanced cancer. The morphological grading 
and clinical staging system lacks the incorporation of molecular heterogeneity that drives 
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disease progression and thus, targeted-molecular agents cannot be appropriately provided to 
individual patients.  
 
Spiral Progression Model 
Recognizing the need for a classification system that includes molecular makers for 
therapy selection in PCa, Logothetis et al. proposed an alternative model of PCa progression 
which incorporates stage-specific molecular drivers that can be targeted by single or 
combination therapies [5]. This alternative model (Fig. 1) consists of an endocrine-driven 
phase, a microenvironment-driven phase and a tumor cell autonomous phase [5]. In the 
endocrine driven phase, tumor growth is dependent on the androgens, testosterone (secreted 
from the testes) and dehydroepiandrosterone (DHEA) (secreted from the adrenal gland), 
which are converted by the enzyme 5-α-reductase (SRD5A) to dihydrotestosterone (DHT). 
DHT binds to androgen receptor (AR) with higher affinity than testosterone and promotes 
cancer cell proliferation and metabolism. SRD5A inhibitors (e.g., finasteride and dutasteride) 
are thus effective in the treatment of low-grade endrocrine-driven cancer, while androgen 
ablation therapy (e.g., Lupron) is effective in the treatment of high-grade cancers that are not 
DHT-dependent [5]. The responses to these therapies are short-lived and resistance soon 
develops as PCa transitions to a paracrine-driven phase and enters the progression spiral (Fig. 
1) where each “turn” of the spiral is driven by molecular marker/s that can be targeted and 
the “pitch” is indicates the duration of time for which the tumors are responsive to targeted 
therapy. Chemotherapeutic modalities have limited success in this phase since multiple  
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Figure 1 - Spiral Progression model   
This alternative model describes different stages of prostate cancer. In the early stage, 
prostate cancer cells are DHT-dependent. Upon entry into the progression spiral where each 
turn is driven by a molecular marker/s, the cancer cells are in paracrine-driven phase. Cancer 
cells can exit from the spiral and enter the cell autonomous stage.  
From Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E and Lin SH 
(2013). Molecular Classification of Prostate Cancer Progression: Foundation for Marker-
Driven Treatment of Prostate. Cancer Discovery 3; 849. Reproduced with Permission 
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factors including changes in AR signaling (AR amplification, mutation, splicing), aberrant 
oncogenic activation (e.g., activation of Src family kinases, Her2, Akt), receptor  
overexpression (e.g., MET, IGF-1R), downregulation of tumor suppressors (e.g, loss of 
PTEN, p53) and paracrine mediated effects (activation of osteoblasts and osteoclasts) can 
drive disease progression and metastatic growth [5]. This progressive disease where patients 
do not respond to androgen ablation therapies is termed as metastatic castrate-resistant 
prostate cancer (mCRPC). According to the alternative model described above, prostate 
cancer cells can exit the spiral and enter a cell autonomous phase where the tumor is 
androgen independent with neuroendocrine features. This late-stage disease is termed as 
neuroendocrine prostate cancer or small cell prostate cancer or anaplastic prostate cancer. 
Surprisingly, whereas earlier stages do not respond well to chemotherapy, this stage responds 
to chemotherapeutic agents [5]. These distinct features of PCa progression and different 
responses to therapies, present the need to better understand stages of PCa progression and 
the underlying genetic, epigenetic and molecular alternations in each stage.  
 
Genetic and Epigenetic Alterations in Prostate Cancer  
There are few signature driving oncogenic mutations in PCa; however, tumor cells 
undergo many genetic and epigenetic alterations that can initiate cancer development and 
further promote its progression. These include copy number alterations, chromosomal 
rearrangements and alterations, epigenetic silencing (DNA methylation), histone 
modifications and chromatin remodeling and miRNA dysregulation. Losses of chromosomes, 
including 8p, 10q, 13q and 17p have been reported [6, 17] by comparative genomic 
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hybridization (CGH), which includes regions for the tumor suppressor genes, NKX3.1, 
PTEN, Rb and p53 respectively. Less frequent chromosome gains of 8q and 7 [18-20] have 
also been reported which include regions for candidate oncogene c-Myc, EGFR and c-Met. 
Most genomic aberrations were identified in the RB, PI3K and RAS/RAF signaling pathway 
by global copy-number and transcriptome profile analysis [21]. Downregulation of tumor 
suppressive gene NKX3.1, located on 8p has been implicated in prostate cancer initiation [6, 
22]; loss of PTEN located on 10q is involved in PCa development and progression; while 
loss of Rb and p53 are associated with invasive PCa and progression to castrate-resistant 
metastatic PCa [6, 23, 24]. The gene loci of c-Myc, 8q24.21 is amplified in advanced prostate 
cancer and in metastases [25], and Myc overexpression in mouse models induces cancer 
initiation and progression to invasive prostate adenocarcinoma [26]. Chromosomal 
rearrangements have been identified with fusion of androgen regulated TMPRSS with ETS 
family of genes [27, 28], an early event in PCa development and associated with more 
aggressive cancer [29]. 
 Epigenetic modifications, in addition to genetic alterations are important in cancer 
initiation and progression. DNA methylation is an epigenetic modification that occurs mostly 
at the cytosines within the CpG islands, found at the 5’untranslated region (UTR) of 
promoters of numerous genes. DNA promoter methylation-induced gene silencing has been 
reported for more than 50 genes in PCa, including Glutathione S-transferase P1 (GSTP1) 
hypermethylation in more than 90% of PCa [30-32]. Epigenetic modifications of histone 
include acetylation, methylation, etc. of the histones and in prostate cancer acetylation of 
H3K18 and methylation of H3K4 has been shown to be predictors of PCa progression [33].  
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Molecular Mechanisms Driving Prostate Cancer Progression 
Several molecular alterations can drive prostate cancer progression that includes 
overexpression and/or activation of receptor and non-receptor protein tyrosine kinases 
(PTKs) that promote PCa growth, development, progression, and metastasis and thus driving 
each spiral of the progression model (Fig. 1). One of the genes implicated in PCa progression 
and metastasis is receptor tyrosine kinase (RTK), c-Met (MET). MET can be activated by 
bindings of its ligand, HGF which leads to receptor dimerization and phosphorylation of 
tyrosines (Tyr), Tyr 1234 and Tyr 1235 in the kinase domain and further phosphorylation of 
Tyr 1349 and Tyr 1356 in the carboxy-terminal substrate docking site leads to MET 
activation and recruitment of signaling molecules [34]. MET/HGF signaling can relay 
activation of downstream signaling cascades important for cell survival, proliferation, 
differentiation, migration, and invasion [35]. MET expression significantly increases with 
PCa progression, and increased MET expression is inversely related to poor prognosis [36]. 
MET is expressed in basal and intermediate cells of normal prostate and is also expressed on 
PCa cells [37]. Androgen deprivation increases MET expression and also increases HGF 
expression in prostate cancer and stromal cells [38, 39]. MET expression is higher in PCa 
tissue compared with normal tissue and in bone metastasis compared with lymph node 
metastasis of PCa [40]. MET receptor is present on stromal cells including osteoblasts, 
osteoclasts and endothelial cells and its ligand HGF is also secreted by stromal cells 
suggesting involvement of the MET/HGF signaling in the bone microenvironment promoting 
survival and growth of tumor and stromal cells [4]. Thus, targeting of MET in advanced bone 
metastatic prostate cancer has been thought to be clinically important however, single agent 
MET inhibitors have not been successful in treating advanced disease [4] and multi-targeted 
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small molecule inhibitors such as Cabozatinib recently failed in Phase III clinical trial. This 
could be due to emergence of compensatory pathways and/or MET re-activation in response 
to inhibitors (Varkaris, unpublished) through different mechanisms that include gene 
amplifications, mutations and ligand independent receptor cross talk. Integrin binding, G 
protein coupled receptors, plexins, CD44, EGFR and RET have all been implicated in ligand 
independent MET activation [41]. In non-small cell lung cancer (NSCLC), MET activation 
through gene amplification is predicted to be one of the mechanisms of EGFR inhibitor, 
gefitinib resistance [42]. In NSCLC, MET can be activated by EGF in a ligand independent 
manner [43] and EGFR can activate MET to promote invasion and brain metastasis [44]. 
However, in PCa, gene amplifications or mutations of MET are extremely rare and receptor 
cross talk mechanisms have not been previously reported. It will be thus important to 
determine whether in PCa, MET can be activated by cross talk with other receptors and 
interactions with soluble factors in the bone microenvironment that contributes to 
development of resistance to MET inhibitors. 
  Axl is another receptor tyrosine kinase that can be activated by its ligand, Gas6 or 
homophillic interactions [45]. Receptor dimerization leads to autophosphorylation and 
activation of downstream signaling that can promote cancer cell proliferation, survival, 
migration, and invasion [46, 47]. Axl expression increases with high-grade prostate cancer 
and in bone metastasis of PCa [46, 48]. Axl protein and mRNA expression are also higher in 
more metastatic PCa cell lines and knockdown of Axl decreases expression of mesenchymal 
markers as well as decreases survival, proliferation, migration and invasion abilities of PCa 
cell lines [49]. Thus, targeting Axl could be beneficial for treatment of advanced PCa. 
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c-Myc (Myc) is a proto-oncogene that regulates cell proliferation and transformation. 
It activates genes involved in cell cycle progression and inhibits genes that are involved in 
cell cycle arrest [50]. c-Myc mRNA expression is increased in laser capture micro-dissected 
(LCM) tumor cells compared to benign epithelial cells [51] and Myc is also overexpressed at 
the protein level in prostate cancer cells [25]. Myc can be upregulated by AR in a ligand 
independent manner in high-grade metastatic PCa [52] and can be post-transcriptionally 
controlled by microRNAs [53]. In transgenic mice, Myc overexpression in the prostate can 
lead to development of prostatic intraepithelial neoplasia (PIN) and followed by progression 
to invasive carcinoma [26]. Myc being a transcriptional factor is hard to target by 
conventional small molecule inhibitors [54], however RNAi-mediated silencing of Myc 
transcription can inhibit tumor initiating capacity and stem-like maintenance of prostate 
cancer cells [55] and strategies targeting Myc expression can be developed for treatment of 
prostate cancer. 
Since, many genes including MET, Axl, c-Myc can contribute to PCa progression, 
targeting these multiple genes could be a better approach for treatment of advanced bone 
metastatic cancer.  
 
Prostate Cancer Metastasis and Tumor Microenvironment 
Prostate cancer mostly commonly metastasizes to the bone, followed by lungs, liver 
and brain. It is not known why prostate cancer cells preferentially metastasize to the bone. 
There are some suggestions that the tumor microenvironment interactions in PCa can 
promote tumor growth and metastases in the bone. The bone microenvironment consists of 
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stromal cells including bone forming osteoblasts, bone dissolving osteoclasts, fibroblasts, 
endothelial cells and immune cells. Many growth factors including IGF-1, and cytokines like, 
IL-6, IL-8, chemokines and extracellular matrix (ECM) proteins secreted in the bone 
microenvironment act on tumor cells enhancing their growth and survival [56]. Tumor cells 
also secrete factors that act upon the stromal cells and alter their properties favoring tumor 
growth. Tumor cells secrete osteoblastic and osteoclastic factors including-BMPs, PTHrP, 
ET-1, PDGF, that act on osteoblasts promoting new bone formation and on osteoclasts 
promoting bone resorption [57, 58]. Osteoclasts and osteoblasts on the other hand secrete 
growth factors including- TGF-β, HGF, IGF-1, etc. that promote tumor cell proliferation and 
survival [57, 58]. Thus, it is important to target both the tumor and the microenvironment 
compartments to disrupt the tumor-microenvironment interactions and have elevated 
therapeutic benefit in metastatic prostate cancer. 
 
Treatment Modalities in Prostate Cancer 
Prostate cancer in its DHT-dependent stage can be treated by surgical interventions 
and/or androgen deprivation therapy (ADT). First generation anti-androgens including 
flutamide, bicalutamide, or first generation androgen synthesis inhibitors including 
ketoconazole can be given to patients with non-metastatic CRPC [59]. However, the 
responses to these therapies are heterogeneous and eventually lead to cancer progression. 
FDA recently approved Abiraterone and Enzalutamide for treatment of metastatic prostate 
cancer [60]. Abiraterone is a CYP17 inhibitor that inhibits androgen biosynthesis while 
Enzalutamide is an androgen receptor antagonist that target androgen receptor activation 
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[60]. These agents have modest improvements in overall survival with development of 
resistance and/or activation of oncogenic pathways that further drives cancer progression. 
Radium 223 (Rad 223), an alpha-emitting radiopharmaceutical that targets the bone matrix is 
used for treatment of bone metastasis in prostate cancer [60]. Rad 223 showed modest 
improvement in overall survival by 3.7 months compared to placebo arm [60]. Small 
molecule inhibitors targeting activation of RTKs (e.g., Cabozatinib for MET) or SFKs (e.g. 
Dasatinib) have severe toxic side effects and are not successful in Phase III clinical trials 
with mCRPC [4]. Thus, there is a need to develop therapeutic approaches that target multiple 
oncogenic pathways to combat resistance as well as target both the tumor and the 
microenvironment for better treatment of metastatic prostate cancer. One such approach is 
through microRNAs that are deregulated in cancer and their replacement or inhibition could 
affect multiple targets involved in cancer development and progression. 
 
MicroRNAs in Cancer 
Regulation through microRNAs (miRNAs) is an important post-transcriptional 
mechanism present in a cell. miRNAs are 18- to 22-nucleotide (nt) post-transcriptional 
modulators that regulate many normal cellular processes, including growth, survival, 
differentiation, cell cycle arrest, aging; and their dysregulation has been implicated in cancer 
development and progression. miRNAs are transcribed from the genome as longer primary 
transcripts (pri-miRNAs) which is cleaved by ribonuclease Drosha (DGCR8) into 70-100 nt 
long hairpin pre-miRNA structures with 3’overhang. These pre-miRNAs are then exported 
into the cytoplasm by exportin 5 (XPO5) where the ribonuclease Dicer further cleaves the 
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hairpin pre-miRNA to ~22 nt long miRNA duplex; and following separation and degradation 
of the other strand, mature miRNA is loaded in the RNA-induced silencing complex (RISC) 
[61, 62]. The mature miRNA is led by the RISC and Argonaute (AGO) proteins to interact 
with the target mRNA at the 3’UTR through partial complementary sequence and inhibits 
protein translation by either inducing silencing or degradation of the target mRNAs [62-64] 
(Fig. 2). It has been reported that miRNAs can also bind to the 5’UTR and ORF and can 
directly bind to DNA to regulate gene expression at the transcriptional level [64]. Thus, 
miRNA can regulate gene expression through many different mechanisms.  
In cancer, miRNAs can act as oncomirs by downregulating tumor suppressor genes or 
can act as tumor suppressive miRs by downregulating oncogenes. It was first reported that in 
B-CLL, the loss of chromosome 13q14, which encodes for tumor suppressive miR-15a and 
miR-16-1, occurs in ~68% of the cases [65]. Amplification of miR-155, an oncogenic 
miRNA has been found in various B cell lymphomas and it is shown to be overexpressed in 
many different hematopoietic cancers and solid tumors [66]. 
Differential expression of miRNA in normal vs. cancer tissue and in indolent vs. 
metastatic disease can be used for targeted therapy and in biomarker development. Since, a 
single miRNA can regulate multiple targets that are involved in various tumorigenic 
processes, miRNA-based therapies can effectively inhibit various oncogenic pathways and 
provide better treatment options than those that are currently available [63]. For example, a 
miRNA that targets multiple tumor promoting genes including, MET, Axl, c-Myc in prostate 
cancer discussed earlier in this introduction could be developed for therapeutic applications. 
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Figure 2 - miRNA biogenesis 
miRNA is transcribed from its gene and then processed by the enzyme Drosha and exported 
from the nucleus by exportin 5. In the cytoplasm, it is further cleaved by the enzyme Dicer to 
get miRNA duplex and following degradation of the second strand, the mature strand is 
loaded on the RISC for target mRNA recognition by complementary base pairing to inhibit 
mRNA translation.  
From Jansson MD and Lund AH (2012). MicroRNA and cancer. Mol. Oncol. 6(6): 590-610. 
Reproduced with permission 
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There are two emerging strategies for miRNA-based therapies for clinical applications. One 
strategy involves inhibiting the function of oncogenic miRs by using antagonists like-
antagomirs, miRNA sponge or locked-nucleic acids (LNAs) that can bind and inhibit specific 
miRNAs. Another strategy involves restoring the expression of tumor suppressive miRNA 
that is downregulated in cancer cells. This can be achieved by delivering mature miRNA 
mimics through polymer, neutral lipid-based or cationic nanoparticle-based approaches [63]. 
miRNA replacement therapy is advantageous because the miRNA mimics are very small in 
size and can be effectively encapsulated and delivered through systemic injections [63]. The 
mimics have the same sequence as the miRNA that is downregulated in cancer and are 
expected to behave in a similar manner thus, eliminating nonspecific off-targets effects [63]. 
A single tumor suppressive miRNA can inhibit multiple oncogenic pathways for example; 
let-7 can inhibit Myc, Ras, cyclin D, CDK6 that are involved in promoting oncogenic 
transformation and cancer cell proliferation [63]. Pre-clinical studies using miRNA delivery 
have been effective in decreasing tumor growth without toxic side effects in animal models 
of various cancers. Polyethylenimine (PEI)-mediated systemic delivery of miR-145 and miR-
33a reduced tumor growth in a mouse model of colon cancer [67]. Atelocollagen mediated 
systemic delivery of miR-16 inhibited prostate tumor growth in the bone in an intra-cardiac 
mouse model [68]. Several approaches including nanoparticle-mediated delivery are 
currently being tested in pre-clinical miRNA therapeutic studies.  
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Chitosan Nanoparticles for Therapeutic Applications 
Nanoparticles are effective delivery vehicles that can be used for delivering drugs or 
small RNAs through oral or systemic injections. There are liposomal, solid-lipid, silica, 
carbon-based and polymeric nanoparticles, each with its unique properties that have the 
potential for clinical application. Chitosan is a polysaccharide derived from deacetylation of 
chitin, which is present in the naturally in fungal cell walls and crustaceans shells [69]. 
Chitosan consists of repeating units of glucosamine and N-acetyl-glucosamine and is 
insoluble at neutral pH but becomes positively charged and soluble at acidic pH [69]. 
Chitosan is a naturally occurring biodegradable, biocompatible, non-toxic, low immunogenic 
polymer and due to its positive charge can effectively bind cell membranes, thus increasing 
cellular permeability [69, 70]. Chitosan nanoparticles can be formulated by incorporating a 
polyanion like tripolyphosphate (TPP) into a solution through constant stirring [71]. Further 
modifications, for e.g., including polyethylene glycol (PEG) can increase its solubility and 
lead to formulation of cross-linked chitosan nanoparticles for delivering drug combinations 
for therapeutic applications [72]. Han et al. demonstrated that chitosan nanoparticle can be 
used for selective delivery in an orthotopic model of ovarian cancer, and silencing of growth-
promoting genes by siRNAs delivered through these nanoparticles result in inhibition of 
tumor growth [70]. Chitosan nanoparticles were used for combination delivery of miR-200 
family members that decreased tumor growth and metastasis in different cancer models by 
inhibiting angiogenesis [73]. Recently, it was shown that systemic delivery of miR-34a 
through chitosan nanoparticles decreased bone metastasis in a breast cancer and melanoma in 
vivo model [74]. Thus, chitosan nanoparticles have been effectively used for small RNAs 
delivery in preclinical models and their physiological properties including biocompatibility 
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and low toxicity makes them an attractive delivery approach for miRNA therapy 
applications. 
 
Role of miR-34a in cancer 
Expression of tumor suppressive miRNA, miR-34 is decreased in several cancers. 
The miR-34 has three family members: miR-34a, miR-34b and miR-34c that share ~80% 
homology in their seed sequence leading to targeting similar genes and having redundant 
functions. However, the expression of miR-34 family members differs in tissue types. miR-
34a is more prevalent than other family members in normal human tissues, except, lung, 
ovary, testes and trachea [75]. The miR-34a gene is located on chromosome 1p3622 while 
miR-34b and miR-34c are transcribed from polycistronic transcript on chromosome 11q23.1. 
Both of these gene loci are frequently downregulated in hematopoietic cancers and miR-34a 
expression is downregulated in many solid tumors including-breast, lung, prostate, liver and 
pancreatic cancers [66, 75, 76]. Expression of miR-34 family members can be induced in a 
p53-dependent [77, 78] and p53 independent manner in different cell types and under 
different conditions [79, 80]. The promoters of miR-34 can be hypermethylated in different 
cancers leading to their downregulation. For example, miR-34a methylation was detected in 
~45% of colon cancer samples and associated with liver metastasis [81]. miR-34a can 
directly target and repress multiple oncogenic proteins including MET, Axl, c-Myc, Notch-1, 
JAG-1, Bcl-2, SIRT-1, CDK4 (Fig. 3) in different cancers like breast, prostate, hepatocellular 
carcinoma, NSCLC, among others  [45, 53, 75, 82, 83]. These results suggest that there are  
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Figure 3 - Role of miR-34a in cancer 
miR-34a belong to the miR-34 family and is transcribed from Chr1p36.22 while its other 
family members are transcribed from gene locus at Chr11q23.1. miR-34a targets and 
downregulates many genes involved in various pathways promoting cancer development and 
progression. 
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multiple mechanisms through which miR-34a expression can be downregulated in cancers 
which leads to upregulation of its targets that can then promote oncogenic transformation,  
cell cycle, proliferation, survival, cancer stemness, metastasis and chemoresistance [75] (Fig. 
3). Thus, miR-34a replacement therapy could be an attractive strategy to inhibit tumor 
growth. Liu et al. showed that miR-34a was downregulated in CD44+ prostate cancer cells 
and it targets CD44 in prostate cancer stem cells (CSCs) [84]. They further show that miR-
34a replacement therapy can inhibit tumor growth in an orthotopic model of PC3cells and 
lung metastasis in LAPC9 model [84]. Systemic delivery of miR-34a in a lipid-based vehicle 
decreased tumor growth without toxic side effects in a subcutaneous model NSCLC and 
decreased expression of its targets –MET, CDK4 and Bcl2 [85]. In another study, neutral 
lipid emulsion based systemic delivery of miR-34a decreased NSCLC growth in an 
orthotopic and KRAS driven transgenic model [86] and in Kras/p53 double transgenic mouse 
model by inhibiting known miR-34a targets [87]. In another mouse model of multiple 
myeloma, miR-34a delivery decreased tumor growth and enhanced survival by decreasing 
cell proliferation and inducing apoptosis [88]. These works have led to the development of 
miR-34a formulation in liposomal injection, MRX34 in Phase I clinical trial for the treatment 
of primary liver cancer.  
In prostate cancer, miR-34a has been shown to be downregulated in prostate cancer 
compared to normal tissue in laser capture microdissected (LCM) specimens [53] and its 
expression decreases with increasing gleason score in FFPE samples [89]. Overexpression of 
miR-34a decreases expression of AR, Notch-1 [90], c-Myc [53], MET, CD44 [84] in prostate 
cancer cells and decreases cancer cell aggressiveness, inhibits proliferation, migration, 
invasion, and decreases orthotopic tumor growth along with inducing apoptosis [75] (Fig. 3). 
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The role of miRNAs in regulating autophagy, a process involved in cell death and/or survival 
is emerging with Liu et al. reporting that miR-34a inhibits autophagy and promotes cell death 
in retinoblastoma cells [91]. However, autophagic process described below is a complex 
network of numerous interacting proteins and several forms of autophagy with diverse 
biological effects in cancer are being discovered.  
 
Autophagy in Cancer 
Autophagy is a cellular degradation process, which is induced in response to 
starvation or stress and leads to clearance of damaged proteins and cellular components [92]. 
Autophagic process induction begins with the formation of phagophore and following 
nucleation which involves the class III phosphatidylinositol 3-kinase (PtdIns3k) complex 
(containing VPS34, Beclin-1, AMBRA-1, ATG14 or UVRAG and BIF1), the vesicle 
elongates to include cytosolic proteins and organelles (Fig. 4). Vesicle elongation involves 
conjugation of phosphatidylethanolamine (PE) to LC3 to form LC3II that is attached on the 
phagophore and helps in phagophore expansion and recognition of cargo. The phagophore 
then matures into double-layered autophagosomes (AP) that can fuse with the lysosomes to 
form single layered autolysosomes (AL) (Fig. 4). The lysosomal enzymes lead to vesicle 
breakdown and degradation of engulfed components. This process requires coordinated 
network of many essential autophagic genes including –Beclin 1, ATG5 and ATG7 among 
others. However, Beclin-1, ATG-5 and ATG-7- independent autophagy has also been 
reported in the literature [93-95]. It is widely accepted that this cellular “self-eating” and 
evolutionary conserved mechanism promotes survival under cellular stress. However, 
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Figure 4 - Autophagic Process 
In canonical autophagy, induction of autophagy from stress, nutrient starvation or other 
conditions leads to nucleation of lipid bilayer to form phagophore, which then elongates to 
include cytoplasmic components and organelles to form double layered autophagosomes 
which can then fuse with lysosomes to form single layered autolysosomes where the 
engulfed components are degraded by lysosome enzymes.  
From Kang R, Zeh HJ, Lotze MT and Tang D (2011) The Beclin 1 network regulates 
autophagy and apoptosis. Cell Death and Differentiation 18, 571–580. Reprinted with 
permission. 
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in the context of cancer, autophagy has been implicated to play a tumor promoting as well as 
a tumor suppressive role.  
Autophagy can be induced in cancer cells as a survival mechanism in response to 
nutrient deprivation, hypoxia, chemotherapeutic and other metabolic stress [92, 96]. 
Autophagy defects are also found in cancers with loss of essential autophagy gene beclin1 
reported in prostate, breast and ovarian cancer. Loss of beclin-1 and atg5 can promote 
tumorigenesis in different mouse models [96]. Autophagy can induce cell death independent 
of apoptosis and has been reported as a cell death mechanism in apoptosis deficient cells. It 
has been shown that prolonged treatment with targeted molecular therapy can induce 
autophagy leading to cell death. In ovarian cancer, inhibition of prolactin (PRL) and its 
receptor PRLR leads to non-canonical Beclin-independent destructive autophagy [97]. 
Inhibition of Akt in sorafenib-resistant HCC can switch protective autophagy to destructive 
death promoting mechanism [98] while Rottlerin can induce autophagy leading to apoptosis 
in breast cancer stem cells (CSCs) [99]. In prostate cancer, CCL2 protects PC3 cells from 
autophagic cell death prolonging their survival in serum-starved conditions through 
PI3K/Akt/survivin pathway and inhibition of this pathway decreases cell survival [100]. 
Thus, autophagy can lead to cell death along with or without apoptosis in different cancer 
cell lines. 
 
Autophagy Regulation by MicroRNAs 
miRNAs have been implicated in the regulation of autophagy either directly by 
targeting mRNAs of autophagic genes or indirectly by modulating autophagy inducers and 
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repressors [101, 102]. miR-101 can inhibit autophagy by targeting ATG4D and RAB5A 
involved in nucleation and elongation of vesicles while miR-30a can target BECN1 and 
reduce rapamycin and cisplatin induced autophagy [101, 103]. While most of the studies 
have focused on negative regulation of miRNAs on autophagy induction, Tazawa, et al. 
reported that miR-7 induces autophagy leading to cell death by downregulating EGFR [104]. 
Under starvation and chemotherapy conditions, miR-34a has been reported to inhibit 
autophagy by downregulating HMGB1 and promoting cell death [91]. However, 
downregulation of miR-34a targets including MET and Axl can induce autophagy along with 
apoptosis in certain cell lines [105, 106] though the mechanism of autophagy induction is not 
known. It is thus, important to further understand the mechanism and the biological effects of 
miR-34a-induced autophagy with the introduction of miR-34a therapy in clinical trials.  
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Summary of Problem and Hypotheses 
Prostate cancer is the second most lethal cancer with most deaths resulting from bone 
metastasis. Several factors including genetic and epigenetic changes leading to multiple 
molecular alterations contribute to prostate cancer initiation and progression. While organ 
confined early-stage disease can be treated with androgen ablation or surgical interventions; 
metastatic disease has dismal survival rates. It is thus essential to develop more effective 
therapeutic approaches for treatment of advanced disease.  
Numerous receptor tyrosine kinases (RTKs) are overexpressed in prostate cancer 
including, MET, IGF1R, Axl and Her2 that play a role in PCa progression. However, it is not 
known whether these RTKs cross talk and activate downstream signaling pathways in 
prostate cancer. One of the goals of this Ph.D. dissertation work was to understand the 
involvement and interactions of RTKs implicated in prostate cancer. I focused on RTK, MET 
that is overexpressed in PCa by studying its activation through another RTK overexpressed 
in PCa, IGF-1R that promotes cancer survival and proliferation. I hypothesized that 
activation IGF-1/1R pathway leads to ligand independent MET activation in prostate cancer 
cell lines. I tested this hypothesis in Chapter 3 by determining MET activation and its effects 
on downstream signaling components after IGF-1/1R pathway activation.  
Activation of multiple oncogenic pathways that drive cancer progression asserts the 
need for therapeutic approaches that target different pathways involved in cancer 
development and growth. Tumor suppressive miRNA, miR-34a is downregulated in many 
cancers and targets some of the genes implicated in prostate cancer including RTKs, MET 
and Axl. The second goal of this Ph.D. dissertation was to determine whether miR-34a 
delivery decreases tumor growth. I hypothesized that decreased miR-34a expression leads to 
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upregulation of targets that promote PCa progression, and thus in vivo miR-34a replacement 
therapy could be a novel strategy for treating advanced PCa. I tested this hypothesis by 
determining miR-34a expression in PCa cell lines and by delivering miR-34a through 
chitosan nanoparticles in in vivo models (Chapter 4 and 5).  
Several studies report that autophagy, involved in clearance of damaged organelles 
and proteins, plays a critical, albeit complex role in cancer. There is evidence for tumor 
promoting as well as tumor suppressive role of autophagy in cancer. Autophagy and 
apoptosis can occur simultaneously or exclusively and promote cancer cell death as 
demonstrated by downregulation of miR-34a targets-Axl and MET that induce autophagy 
and apoptosis in cell line models. The third goal of this Ph.D. dissertation work was to 
determine whether miR-34a induces autophagy. To address this question, I performed miR-
34a overexpression in multiple cell lines and further knocked down essential genes involved 
in the autophagic pathway to determine the mechanism of miR-34a-induced autophagy 
(Chapter 6 and 7).   
The work in this dissertation has led to the understanding that MET may be activated 
by multiple receptor tyrosine kinase receptors, and multi-targeting of these receptors may be 
important therapeutically. The work in this dissertation further presents miR-34a delivery as 
an alternative strategy for treatment of bone metastatic prostate cancer for which current 
therapies are not very effective. Finally, this work identified a novel role of miR-34a in 
inducing a non-canonical form of autophagy that occurs along with apoptosis and is involved 
in promoting cell death. 
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Chapter 2 
Materials and Methods  
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This Chapter is partly based upon “Varkaris A*, Gaur S*, Parikh NU, Song JH, Dayyani F, 
Jin JK, Logothetis CJ, and Gallick GE (2013) Ligand-independent Activation of MET 
Through IGF-1/IGF-1R Signaling. Int J Cancer. 2013 Oct 1;133(7):1536-46”, with 
permission from International Journal of Cancer and Wiley. 
* Equal contribution, shared first authorship. 
 
Materials and Methods: 
Cell lines and media: 
PC3 and PC3MM2 cells were a gift from Dr. Isiah Fidler’s laboratory at MD Anderson. 
LNCaP and MDA MB 231 cells were purchased from American Type Culture Collection, 
and C42B4 and PC3MM2-LG (luciferase-GFP labeled) cells were a gift from Dr. Sue Hwa 
Lin’s laboratory at MD Anderson. A549 were a gift from Dr. John Heymach, HepG2 were a 
gift from Dr. Mein Chie Hung and SKOV3 cells were provided by Dr. Anil Sood’s 
laboratory at MD Anderson. PC3 cells with doxycycline inducible shRNA knockdown of 
ATG7 (PC3 shATG7 no Dox/+Dox) were provided by Dr. Daniel Frigo’s laboratory at 
University of Houston. PC3, PC3MM2, A549, HepG2 and MDA MB 231 cells were 
maintained in Dulbecco’s modified Eagle medium nutrient mixture F-12 (DMEM/F12, 
Sigma, St. Louis, MO) with 10% fetal bovine serum (Sigma, St. Louis, MO) and 1% 
penicillin/streptomycin (Hyclone, Logan, UT). LNCaP cells were cultured in RPMI-1640 
media (Sigma, St. Louis, MO) with 10% fetal bovine serum (FBS), supplements (sodium 
pyruvate, non-essential amino acids, and modified Eagle medium vitamin solution; 
Invitrogen), and 1% penicillin/streptomycin. C42B4, DU145 and PC3 shATG7 no Dox/+Dox 
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cells were cultured in RPMI-1640 media (Sigma, St. Louis, MO) with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin. SKOV3 cells were maintained in RPMI-1640 
media with 15% FBS and 0.1% gentamicin (Gemini Bioproducts, Calabasas, CA). 800 ng/ml 
of Doxycycline was used for inducing knockdown of ATG7 as described previously [107]. 
Cells were checked every six months and found to be mycoplasma free. The M.D. Anderson 
Cancer Center Department of Systems Biology performed fingerprinting analysis to confirm 
the correct identity of the cell lines. All cell lines were validated by STR DNA fingerprinting 
using the AmpF_STR Identifiler kit according to manufacturer's instructions (Applied 
Biosystems cat 4322288). The STR profiles were compared to known ATCC fingerprints 
(ATCC.org), and to the Cell Line Integrated Molecular Authentication database (CLIMA) 
version 0.1.200808 (http://bioinformatics.istge.it/clima/) (Nucleic Acids Research 37:D925-
D932 PMCID: PMC2686526). The STR profiles matched known DNA fingerprints. 
 
Reagents and chemicals 
IGF-1 (Catalog # 291-G1) and HGF (Catalog # 294-HGN-005) were purchased from R&D 
Systems (Minneapolis, MN). Actinomycin D (Catalog # A1410) was purchased from Sigma. 
Dasatinib (SPRYCEL®) was a gift from Bristol-Myers Squibb (Princeton, NJ).   
 
miRNA Transfection:  
Transient transfections were performed using Lipofectamine 2000 transfection reagent 
(Invitrogen, Carlsbad, CA) for 24 hours, or 48, 72 or 96 hours for time course experiments. 
Briefly, 100,000 or 200,000 cells were placed in a 6-well plate in growth media without 
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antibiotics 24 hours prior to transfection. Cells were then transfected with either negative 
control (N.C.) miRNA or miR-34a mimics/precursors (Ambion, Austin, TX) at a final 
concentration of 30 nM, according to the manufacturer’s instructions.  
 
RNA isolation and quantitative polymerase chain reaction (qPCR): 
Total RNA was isolated from the cells by using RNeasy mini kit (Qiagen, Valencia, CA) or 
using the mirVana kit (Ambion, Austin, TX) according to the manufacturer’s instructions. 
For IGF-1/1R and MET activation studies, cells were serum starved 24 hours prior to IGF-1 
stimulation and then 100 ng/ml of IGF-1 was added in serum free media for 0, 18 and 24 
hours. To determine miR-34a and U6 (endogenous control) expression, 10 ng of total RNA 
was reverse transcribed using the TaqMan miRNA reverse transcription kit (Applied 
Biosystems, Foster City, CA). qPCR was performed on the Agilent 3000P system using the 
human miR-34a and U6 miRNA TaqMan expression assays and the TaqMan Universal PCR 
master mix (Applied Biosystems, Foster City, CA). Relative miR-34a expression was 
determined using the gene comparative CT method. For gene expression analysis, 200 ng of 
total RNA was reverse transcribed using ThermoScriptTM RT-PCR system for First strand 
cDNA synthesis (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. 
Gene expression was then determined by qPCR using the KiCq Start SYBR Green kit 
(Sigma, St. Louis, MO) on the Agilent 3000P system. The primers sequences used for gene 
expression SYBR Green qPCR are listed in Table 1. 
 
 
 
 
30 
  
 Table 1 - List of Primers and siRNA Sequences  
mRNA/siRNA  Sequence ID Primer sequence 
Axl Axl-F 5’-CGCAGGAGAAAGAGGATGTC-3’ 
 Axl-R 5’-ACCTACTCTGGCTCCAGGATG-3’ 
c-Met Met-F 5’-CAGATGTGTGGTCCTTTG-3’ 
 Met-R 5’-ATTCGGGTTGTAGGAGTCT-3’ 
c-Myc Myc-F 5’-TCAAGAGGTGCCACGTCTCC-3’ 
 Myc-R 5’-TCTTGGCAGCAGGATAGTCCTT-3’ 
ATG5 ATG5-F 5’-GAGTAGGTTTGGCTTTGGTTGA-3’ 
 ATG5-R 5’-CGTCCAAACCACACATCTCG-3’ 
ATG7 ATG7-F 5’-GCATCCAGAAGGGGGCTATG-3’ 
 ATG7-R 5’-AGGCTGACGGGAAGGACAT-3’ 
BECN1 BECN1-F 5’-GCGATGGTAGTTCTGGAGGC-3’ 
 BECN1-R 5’-AGACCCTTCCATCCCTCAGC-3’ 
18s rRNA 18S-F 5’-GTAACCCGTTGAACCCCATT-3’ 
 18S-R 5’-CCATCCAATCGGTAGTAGCG-3’ 
siATG5 #4 siATG5 #4-F 5’-GGUUUGGACGAAUUCCAACUUGUUU-3’ 
 siATG5 #4-R 5’-GAUCACAAGCAACUCUGGAUGGGAU-3’ 
siATG5 #5 siATG5 #5-F 5’-UCUUCGAAGUGAAGCUUCCAGAAAU-3’ 
 siATG5 #5-R 5’-CCAAUCCUGUGAGGCAGCCUCUCUA-3’ 
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Enzyme-linked Immunosorbent Assay 
To examine the endogenous secretion of HGF, PC3 cells were serum starved for 24 hours 
and then stimulated with IGF-1 (100 ng/ml) for 0, 18 and 24 hours. Cell culture media was 
harvested and analyzed in triplicate by human HGF Quantikine ELISA kit (R&D Systems), 
according to the manufacturer's instructions.  
 
Immunoblotting: 
For in vitro studies of IGF-1/1R and MET activation, cells were serum starved for 24 hours 
prior to stimulation with growth factors. For the IGF-1 time-course study, 100 ng/ml of IGF-
1 was used in serum free media for different time points. For the IGF-1 dose-dependent 
study, 0, 10, 25, 50, 100 and 200 ng/ml of IGF-1 were used to stimulate the cells.  For 
Dasatinib studies, cells were pretreated with 100 ng/ml Dasatinib before stimulation with 100 
ng/ml IGF-1 or 15 ng/ml HGF for 24 hours and 10 minutes respectively. Protein lysates were 
prepared using RIPA B lysis buffer (150mM NaCl, 5mM ethylenediaminetetraacetic acid, 
20mM sodium phosphate buffer, and 1% Triton X-100, pH 7.4, along with 1 tablet of 
protease and phosphatase inhibitor cocktail (Roche, Indianapolis, IN). For in vivo samples, 
tumor sections were cut and homogenized by magnetic beads in RIPA A lysis buffer (1% 
Triton X-100, 0.% SDS, 0.5% sodium deoxycholate, 150mM NaCl, 5mM EDTA, 5mM 
sodium pyrophosphate, 20mM sodium phosphate buffer, pH 7.4 along with 1 tablet of 
protease and phosphatase inhibitor cocktail). Total protein lysates (15 or 30 µg) were loaded 
onto an 8% or 12% polyacrylamide gel, which were then transferred to a polyvinylidene 
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difluoride (PVDF) membrane and blocked with 5% milk in tris-buffered saline with Tween-
20. Membranes were probed with specific primary antibodies: c-Met (C12; Santa Cruz 
Biotechnology, Santa Cruz, CA), Axl, cleaved caspase 3, LC3B, Beclin-1, ATG5 and ATG7, 
phospho-Met Y1234/35, phospho-Met Y1349, phospho-Src Y416, Akt, phospho-Akt (S473), 
MAPK, phospho-MAPK, IGF-1R, phospho-IGF-1R beta Y1135/36, ERK1/2 (Cell Signaling, 
Danvers, MA), Src (EMD Millipore, Temacula, CA), c-Myc (Santa Cruz Biotechnology), 
GAPDH (EMD Millipore), Vinculin (Sigma) and horseradish peroxidase-conjugated goat 
anti-mouse or goat anti-rabbit secondary antibody (Bio-Rad, Hercules, CA). 
 
Migration and invasion assay: 
Migration and invasion assays were performed using migration and invasion assay inserts 
(BD Biosciences, Bedford, MA). For IGF-1/1R and MET activation studies, PC3 cells 
expressing the non-targeting and shMET targeting vector were serum starved for 24 hours 
and then incubated with IGF-1 (100 ng/ml) for 24 hours in a culture dish. Cells were 
trypsinized and for each cell type, a total of 50,000 cells were seeded on top of the inserts in 
serum-free media.  Media containing IGF-1 (100 ng/ml) or HGF (15 ng/ml) was used as 
chemoattractant and cells were allowed to migrate for 24 hours. A total of 100, 000 cells 
were seeded on top of the inserts in serum-free media 24 hours after transfection with 
negative control or miR-34a mimic. Serum-free media was used as a chemoattractant and 
cells were allowed to migrate or invade for 24 hours. The bottom of the inserts was then 
stained with Hema-Stain (Millipore, Temacula, CA). The number of migrated or invaded 
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cells for five fields was counted under a bright-field microscope and plotted as the number of 
cells migrated or invaded per field. Each experiment was performed in triplicate. 
 
Cell Proliferation assay:  
For measuring cell viability, The CellTiter 96® AQueous Non-Radioactive Cell Proliferation 
Assay kit (Promega, Madison, WI) was used according to the manufacturer’s instructions. 
Briefly, 1000 N.C. or miR-34a transfected cells were plated in a 96-well plate for 48, 72 and 
96 hours post-transfection time points of cell viability in growth media. A solution of MTS 
and PMS was added to each well, incubated at 37°C 5% CO2 for 2 hours and absorbance 
measured at 490 nm by EnVision® multilabel reader (Perkin Elmer, Shelton, CT). Cell 
proliferation using Hoechst 33342 dye (Life Technologies) was performed according to 
manufacturer’s instructions. Briefly, 2000 N.C. or miR-34a transfected cells with or without 
siATG5 and siATG7, and with or without shATG7 or shBeclin-1 were seeded in a 96-well 
plate and fluorescence from Hoechst dye was measured for different time points by a plate 
reader and plotted as fold change relative to control (N.C. at 48h).   
 
Flow cytometry 
Propidium iodide (PI) and RNAse A (Sigma) solution was prepared according to the 
manufacturer’s instructions. For cell cycle analysis, cells transfected with N.C. or miR-34a 
for different time points were fixed in 70% Ethanol overnight. Fixed cells were then 
resuspended in 50 µg/ml PI solution in PBS for 1 hour in the dark and then 0.2 mg/ml 
DNAase-free RNase A was added and the samples incubated at 37°C 5% CO2 for 30 
minutes and read on Beckman Coulter Gallios flow cytometer and analyzed on Kaluza® 
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Software (Beckman Coulter). Singlet cell population was gated to exclude cell aggregates 
and percentage of cells in sub-G1, G1, S and G2M phase were recorded. GFP-Certified® 
Apoptosis/Necrosis detection kit (Enzo Life Sciences, Farmingdale, NY) was used for 
detection of early and late-stage apoptotic as well as necrotic cells. An Annexin V-EnzoGold 
(enhanced Cyanine-3) (Ex/Em: 550/570nm) conjugate was used for detection of early stage 
apoptotic cells in the FL2 channel and Necrosis Detection Reagent (Red) similar to the red-
emitting dye 7-AAD (Ex/Em: 546/647nm), was used for late apoptosis and necrosis detection 
in FL3 channel by FACS Gallios. Acridine Orange (AO) (Life Technologies) was used to 
measure acidic vesicular organelles (AVOs). Cells transfected with N.C. or miR-34a for 
different time points were incubated with 1ug/ml acridine orange for 30 min in the dark. In 
AO-stained cells, the cytoplasm or nucleolus fluoresce bright green and dim red, whereas 
acidic compartments fluoresce bright red. Green (510–530 nm) and red (>650 nm) 
fluorescence emissions from 10,000 cells illuminated with blue (488 nm) excitation light 
were measured with a FACS Gallios.  
 
Transmission Electron Microscopy (TEM) 
Samples fixed with a solution containing 3% glutaraldehyde plus 2% paraformaldehyde in 
0.1 M cacodylate buffer, pH 7.3 were washed in 0.1 M  cacodylate buffer and treated with 
0.1% Millipore-filtered buffered tannic acid,  postfixed with 1% buffered osmium tetroxide 
for 30 min, and stained en bloc with 1% Millipore-filtered uranyl acetate. The samples were 
washed several times in water, then dehydrated in increasing concentrations of ethanol, 
infiltrated, and embedded in LX-112 medium. The samples were polymerized in a 60°C oven 
for 2 days. Ultrathin sections were cut in a Leica Ultracut microtome (Leica, Deerfield, IL), 
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stained with uranyl acetate and lead citrate in a Leica EM Stainer, and examined in a JEM 
1010 transmission electron microscope (JEOL, USA, Inc., Peabody, MA) at an accelerating 
voltage of 80 kV.  Digital images were obtained using AMT Imaging System (Advanced 
Microscopy Techniques Corp, Danvers, MA). Mr. Kenneth Dunner, Jr., performed TEM at 
the TEM core (Institutional Core Grant #CA16672 High Resolution Electron Microscopy, 
UTMDACC). 
 
siRNA and shRNA transfection 
Ready-to-transfect short hairpin (sh) RNA–GFP–puromycin constructs against human IGF1-
R (#SR302344) and Src (#SR304574) were purchased from OriGene Technologies 
(Rockville, MD). An universal non-targeting negative control shRNA (#SR30004) was 
provided by the manufacturer. An activated Src (Y527F) expression vector was used as 
described previously (Allgayer, et al. JBC 1999). Cells were transfected using Fugene 6 
reagent (Roche) or JetPRIME (Polyplus transfection, Radnor, PA) according to the 
manufacturer’s instructions. Lentiviral shc-met constructs were a gift from Dr. Menashe Bar 
Eli at The University of Texas MD Anderson Cancer Center. Stable clones were selected 
with puromycin or sorted with GFP. Target knockdown was verified 3–4 weeks after 
transfection by western blots. Two siRNA sequences each for ATG5 and ATG7 were 
provided by Dr. Daniel Frigo’s laboratory. PC3 cells were transfected with 100nM of 
siATG5 or siATG7 sequences using DharmaFECT1 (GE Healthcare, Lafayette, CO) 
transfection reagent and 24 hours later, siATG5 or siATG7 cells were transfected with N.C. 
or miR-34a using lipofectamine 2000. Lentiviral shRNA constructs for Beclin-1 were 
provided by MD Anderson shRNA and ORFeome core facility. GIPZ lentiviral shBeclin-1 
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(GE Healthcare) constructs were packaged in lentivirus and PC3 cells were transduced with 
the concentrated vial titer with 8 μg/ml polybrene and following infection GFP positive cells 
were sorted by Becton Dickinson FACS Aria II to get shBeclin-1 cells.  
 
Immunohistochemistry (IHC) and Immunofluorescence (IF) 
Paraffin embedded tumor sections were deparaffinzed and hydrated. Citrate buffer (0.1M , 
pH 6.0)  was used for antigen retrieval, 3% H2O2 (Fisher Scientific, fair Lawn, NJ) in PBS 
was used for endogenous peroxidase blocking and 4% fish gelatin (Electon Microscopy 
Sciences, Hatfield, PA) was used for protein blocking. Met (Santa Cruz) or Axl (Thermo 
Scientific) primary antibody diluted in 4% fish gelation were added to the slides overnight in 
a humidity chamber at 4°C. Slides were then washed with PBS and incubated with MACH4 
polymer (Bio Care Medical, Concord, CA) for 1 hour at RT. DAB (Dako, Carpinteria, CA) 
chromogen was used for visualization of the signal and the nuclei were counterstained with 
Hematoxylin (Sigma). Slides were then dried and mounted with Universal mount and 
examined under bright field microscope. For TUNEL staining, DeadEnd colorimetric TUN-
EL system (Promega) was used according to manufacturer’s instructions. Briefly, FFPE 
slides were deparaffinized and antigen retrieval performed with 1X Dako Antigen Retrieval 
buffer. Slides were then washed with PBS, blocked with 3% H2O2 in methanol for peroxidase 
blocking and in 4% fish gelatin for protein blocking. The slides were incubated with 4% 
paraformaldehyde in PBS for 10 minutes at RT, washed with PBS, incubated in 0.2% 
TritonX-100 in PBS for 15 min at RT, washed with PBS and incubated with Equilibration 
buffer (Promega) for 10 min at RT. TUNEL incubation buffer (Promega) was added to each 
slide for 1 hour at 37°C in the dark. Slides were washed in 2X SSC (Pomega) and 
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counterstained with Hoechst mounting media (Life Technologies) and visualized under 
fluorescence microscope. IHC and IF images were quantified by ImageJ software as 
previously described [108]. 
 
In situ hybridization(ISH): 
Clinical sample slides were obtained from MDACC GU Medical Oncology department. 
H&E slides for each sample were provided along with unstained freshly cut slides containing 
normal and prostate tumor samples. DIG-labeled probed for miR-34a and U6 endogenous 
control were purchased from Exiqon (Woburn, MA) and in situ hybridization (ISH) was 
performed according to manufacturer’s instructions by the Center for RNA Interference and 
non-coding RNA at MD Anderson. 
 
Animal studies: 
One million PC3MM2 cells were injected sub-cutaneously in nude mice. One week after cell 
injection, mice were randomized and divided into Control (N.C.) or miR-34a group. Chitosan 
nanoparticles complexed with N.C. or miR-34a were prepared by the Center for RNA 
Interference and non-coding RNA at MD Anderson. Nanoparticles containing N.C. or miR-
34a were delivered through tail vein injection, every three days for two weeks. Tumor 
volume was measured by caliper instrument every three days. After two weeks of treatment, 
the animals were sacrificed and tumors harvested for protein, IHC, ISH and IF. For intra-
femur experiment, 1x 106 PC3MM2-LG cells labeled with luciferase and GFP were injected 
in the femur of the mice. Ten days after cell injection, mice were randomized into two 
groups- control and miR-34a. The chitosan nanoparticles containing N.C. or miR-34a were 
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delivered via tail-vein injection every three days for three weeks. Tumor growth was 
monitored through bioluminescence imaging (IVIS 200) and tumor volume was measured 
before the start of treatment and at the end of treatment by magnetic resonance imaging 
(MRI) (Bruker 4.7T). Micro CT imaging was performed on the Explore Locus RS pre-
clinical in vivo scanner (GE Medical Systems, London Ontario) to visualize bone integrity at 
the end of the experiment in control and miR-34a treated mice. 
 
Statistics: 
Student’s t tests and one-way ANOVA analysis of variance were used for all statistical 
comparisons and a p value of <0.05 was considered statistically significant. Statistical 
analyses were performed using the GraphPad Prism software. 
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Chapter 3 
Ligand-independent MET Activation by the IGF-1/1R Pathway 
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This Chapter is based upon “Varkaris A*, Gaur S*, Parikh NU, Song JH, Dayyani F, Jin JK, 
Logothetis CJ, and Gallick GE (2013) Ligand-independent Activation of MET Through IGF-
1/IGF-1R Signaling. Int J Cancer. 2013 Oct 1;133(7):1536-46”, with permission from 
International Journal of Cancer and Wiley. 
* Equal contribution, shared first authorship. 
 
 
Multiple receptor and non-receptor tyrosine kinases promote metastatic growth of prostate 
cancer resulting in numerous clinical trials with small molecule inhibitors focusing on 
targeting these kinases. Unfortunately, most of the clinical trials have not demonstrated 
significant improvements in survival. There are multiple reasons for lack of success of these 
inhibitors including involvement of multiple drivers of PCa progression as discussed in the 
spiral model (see Introduction). Activation of alternative compensatory pathways or 
activation of targeted kinase through non-canonical mechanism/s could also result in failure 
of the inhibitors. An example of a tyrosine kinase receiving considerable attention in prostate 
cancer is MET. MET is a receptor tyrosine kinase involved in embryonic development and in 
adults MET facilitates tissue regeneration [34, 109]. In cancer, aberrant expression and 
activation of MET can promote tumor progression by activating MAPK signaling, PI3K-Akt 
axis and STAT pathway involved in cell invasion, migration, survival and proliferation [34, 
41]. In the past few years, several inhibitors have targeted MET oncogene, frequently 
associated with progression of solid tumors, including antibodies targeting its ligand HGF; 
antibodies targeting the receptor, and small molecule inhibitors targeting the kinase activity. 
While trials are ongoing, many have not been promising as exemplified in the recent failure 
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of cabozatinib, a multi-kinase inhibitor with MET and VEGFR2 as the principle targets. 
These failures demonstrate the necessity to understand more about the regulation of the 
targeted kinase. More evidence is accruing for receptor cross talks, and ligand independent 
pathways of MET activation have been reported in other cancers [41]. However, in prostate 
cancer (PCa), ligand independent MET activation through other growth factor receptors has 
not been investigated. In this chapter, I analyzed the ability of the IGF-1/1R pathway, 
aberrantly activated in PCa [110] and in PCa bone metastasis [111], to affect MET signaling. 
I hypothesized that activation of IGF-1/1R pathway leads to activation of MET and 
downstream signaling components that promote tumorigenic and metastatic properties of 
PCa cells. To test this hypothesis, I used PCa cell line, PC3 with high levels of MET and 
IGF-1R receptor that are representative of the majority of metastatic PCa tumors [40, 112] 
and examined the effects of IGF-1 stimulation on MET phosphorylation. I identified one of 
the essential components required to mediate IGF-1/1R induced MET activation and further 
determined the effects of MET inhibition on IGF-1-mediated migration in PC3 cells. 
 
IGF-1 induces delayed activation of MET in PCa cell lines and xenograft tumors 
Insulin-like Growth Factor (IGF) is aberrantly expressed in the microenvironment of 
prostate cancer bone metastases and known to be a poor prognostic marker for PCa survival 
[113]. To determine if IGF-1 affected MET phosphorylation, a time course assay was 
performed in which IGF-1 was added to serum-starved cells and activation of signaling 
enzymes was examined as described in Materials and Methods.  
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As shown in Fig. 5, robust activation of IGF-1R was observed within 10 min, with no 
activation of MET at this time. Activation of Src, Akt, and MAPK were observed with 
similar kinetics to IGF-1R activation (Fig. 6), as expected. No change in protein expression 
was observed for any of these signaling enzymes. In contrast to the acute activation of 
signaling enzymes after IGF-1 addition, MET phosphorylation was observed beginning at 
12h, reaching maximal levels at 18h, with sustained phosphorylation for at least 24h after 
stimulation of PC3 cells with IGF-1 (Fig. 5). Both Y1234-1235 (tyrosine kinase domain) and 
Y1349 (multi-substrate docking) sites were phosphorylated (Fig. 5), suggesting full 
activation of MET occurs at these later time points. No differences in MET protein and 
mRNA expression were evident by immunoblotting (Fig. 5) and qPCR (Fig. 7) respectively.  
To determine if IGF-1 induction of MET phosphorylation were dose-dependent, PC3 
cells were stimulated with different doses of IGF-1 ranging from 10-200 ng/ml.  Under these 
conditions, IGF-1R phosphorylation increased at each concentration of IGF-1 (Fig. 8). In 
contrast, 25 ng/ml IGF-1 was sufficient to induce delayed phosphorylation of MET, and no 
further increases in phosphorylation were observed with higher concentrations of IGF-1. 
These results suggest a threshold of IGF-1R activation is sufficient to fully induce MET 
phosphorylation. MET and IGF-1R protein levels remain unchanged under these conditions 
(Fig. 8). 
To examine the magnitude of MET phosphorylation due to IGF-1 (100ng/ml) relative 
to HGF (15ng/ml), PC3 cells were stimulated with these growth factors for 10 min and 24h 
and activation of IGF-1R and MET were examined. IGF-1 induced a strong delayed  
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Figure 5 - IGF-1 induces delayed MET activation 
IGF-1 was added (100 ng/ml) to PC3 cells and expression and phosphorylation of IGF-1R 
and MET was examined at indicated times by immunoblotting. 
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Figure 6 - IGF-1 phosphorylates downstream signaling components  
IGF-1 was added (100 ng/ml) to PC3 cells and expression and phosphorylation of Akt, Src 
and MAPK was examined at indicated times by immunoblotting.  
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Figure 7 - Expression of MET following IGF stimulation of PC3 cells   
To determine if IGF-1 increased the expression of c-met RNA, cells were treated with IGF-1 
and c-met RNA was measured by qPCR 18 and 24h after IGF-1 addition. Expression was 
normalized to 18s RNA expression. Data represents Mean and SEM from three independent 
experiments 
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Figure 8 - Dose-dependent effects of IGF-1 on receptor activation 
Different concentrations of IGF-1 were added to PC3 cells at indicated times and the 
magnitude of MET and IGF-1R activation was examined. 
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activation of MET at 24h that was only slightly less than the rapid (10 min) MET 
phosphorylation by HGF (Fig. 9), demonstrating that activation of MET by IGF-1 is likely to 
activate MET functions.  
Next, the effects of IGF-1 stimulation on MET activation in PC3 xenograft tumors 
were examined. Briefly, 20µl of IGF-1 (100 ng/ml) were injected directly into established 
PC3 xenografts and tumors were harvested 24h after injection. Immunoblotting analysis 
showed that treated tumors had significantly higher levels of MET and IGF-1R 
phosphorylation compared to control tumors, whereas no changes in MET and IGF-1R 
expression were observed (Fig. 10). These experiments demonstrate that, IGF-1 is capable of 
inducing MET phosphorylation in vitro and in vivo.    
 
IGF-1-induced delayed MET activation is HGF-independent   
HGF is the sole known ligand of MET [34, 41]. To examine if endogenous 
expression/secretion of HGF could play a role in IGF-1-mediated MET activation, HGF 
mRNA was examined by qPCR in PC3 cells treated with IGF-1 for time points that 
correspond to minimal and maximal MET activation by IGF-1. The results show no 
statistically significant differences between control and treated groups (Fig. 11A). To further 
examine potential HGF expression, cell culture media from each group was harvested and 
levels of HGF were determined by enzyme-linked immunoabsorbent assay (ELISA). 
Secreted HGF levels were beneath the level of detection in all groups (Fig. 11B), suggesting 
that PC3 cells do not secrete HGF before or after IGF-1 addition. 
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Figure 9 - Comparison of HGF and IGF induced MET activation  
IGF-1 (100 ng/ml) and HGF (15 ng/ml) were added to PC3 cells at indicated times and 
activation of MET and IGF-1R was examined. 
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Figure 10 - IGF-1 induces MET activation in PC3 tumor xenografts  
PC3 tumors were grown subcutaneously until they reached a volume of 500 mm3.  IGF-1 
(100 ng/ml, 20µl total volume) was injected into the tumor. Tumors were harvested 24h later, 
and expression and phosphorylation of IGF-1R and MET was examined. 
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 Figure 11 - Expression of HGF after IGF-1 addition 
Total RNA was isolated from PC3 cells 24h after IGF-1 addition (100ng/ml), and HGF 
expression was examined by qPCR (A) and ELISA (B). Data represent Mean and SEM from 
three independent experiments.    
A 
B 
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IGF-1-mediated MET phosphorylation requires IGF-1R activation  
To examine whether IGF-1R activation were required for “lateral” MET 
phosphorylation, we generated a PC3 cell line in which IGF-1R was stably knocked down by 
expression of an shIGF-1R construct as described in Materials and Methods.  Expression of 
IGF-1R was reduced >90% (Fig. 12, lane 5 and 6). When the shIGF-1R cells were stimulated 
with IGF-1, delayed MET phosphorylation was abolished; demonstrating activation of IGF-
1R is required for inducing MET phosphorylation (Fig. 12, lane 5 and 6). 
 
Src activation is essential for IGF-1-induced delayed MET activation 
In a study of Dulak et al. tyrosine kinase, Src, was shown to be an essential mediator 
of lateral activation of MET by EGFR [43]. To examine potential roles of Src family kinases 
in delayed MET activation by IGF-1R, I first used the multi-targeted SFK inhibitor, 
dasatinib. PC3 cells were pretreated with 100 nM of dasatinib for 2h before stimulating with 
IGF-1 and HGF for 24h and 10 min respectively. Under these conditions, IGF-1-induced 
delayed MET activation was abolished, suggesting that activation of a Src family kinase may 
be required for delayed MET phosphorylation (Fig 13).  In contrast, dasatinib had little effect 
on HGF-induced direct MET activation (Fig 13). Decreases in MET activation were 
observed in dasatinib only treated cells (Fig 13, lane 2) suggest that dasatinib might have a 
small effect on MET phosphorylation (dasatinib is a multi-kinase inhibitor). To determine if 
activation of Src (as opposed to other Src family kinases) were essential to delayed MET 
phosphorylation by IGF-1, I stably expressed a shRNA for Src in PC3 cells.  As shown in 
Fig. 12, greater than 90% knockdown of Src was observed (Fig 12, lane 3 and 4).   
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Figure 12 - Effects of IGF-1 and Src knockdown on IGF-1-mediated MET activation 
IGF-1 (100ng/ml) was added to non-targeting cells or cells with stable knockdown of IGF-
1R (shIGF-1R) or Src (shSrc), following which MET phosphorylation was examined. 
Vinculin was used as a loading control.   
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Figure 13 - Effects of Dasatinib on IGF-1-mediated MET activation 
PC3 cells were pre-treated with100nM of Dasatinib for 2h after which they were stimulated 
with IGF-1 (100 ng/ml) for 24h or HGF (15 ng/ml) for 10min. MET and Src phosphorylation 
were then examined. 
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As with non-targeting clones, IGF-1 was added and MET phosphorylation was examined 18h 
later. In PC3 cells expressing a non-targeting shRNA, MET was phosphorylated under these 
conditions (Fig. 12, lane 1 and 2).  In contrast, the shSrc cells were unable to induce delayed 
MET activation, with expression of MET unchanged, suggesting Src is required for IGF-1 
induced MET activation (Fig. 12, lane 3 and 4). To further determine whether Src activation 
was required for IGF-1-induced MET phosphorylation, I transfected PC3 ShSrc cells with a 
plasmid harboring a Src mutant (Y527F) that leads to constitutive Src activation and then 
stimulated the cells with IGF-1 for 24h. Expression of an activated Src led to MET 
phosphorylation in the presence or absence of IGF-1 (Fig. 14), suggesting Src activation 
alone is necessary and sufficient to trigger the cascade leading to MET activation.  
 
Inhibition of transcription abolishes IGF-1R-mediated MET phosphorylation  
Since, MET phosphorylation occurs much later than activation of other signaling 
intermediates (Src, Akt, MAPK), I determined if transcription were required for IGF-1R to 
MET cross talk. For these experiments, PC3 cells were treated with the pan-transcription 
inhibitor, actinomycin D, alone or in combination with IGF-1 for time points corresponding 
to the maximal IGF-1-induced MET activation. Lack of synthesis of the precursor of MET 
(upper band, Fig. 15) indicates actinomycin D blocked de novo c-met mRNA synthesis. 
Processed MET (lower band) was still present, as expected. These results suggest no further 
transcription of MET occurred under these conditions. Successful inhibition of transcription 
abolished IGF-1-induced MET activation (Fig. 15), whereas IGF-1-induced IGF-1R   
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Figure 14 - Src activation is required for IGF-1-mediated MET activation 
PC3 cells with stable knockdown on Src (PC3shSrc) were transfected with a constitutively 
active SRC (Src Y527F) mutant for 48h followed by stimulation with IGF-1 (100 ng/ml) for 
24h. Phosphorylation of MET (pY1349), IGF-1R and Src were then examined after 24h of 
IGF-1 stimulation. 
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Figure 15 - Inhibition of transcription abolishes IGF-1R-mediated MET 
phosphorylation  
Actinomycin D (0.01 mg/ml) was added to cells to inhibit transcription. IGF-1 was then 
added (100 ng/ml) and IGF-1R and MET phosphorylation was examined 18h (lanes 3 and 5) 
and 24h (lanes 4 and 6) later. 
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activation (which occurs within 10 min and does not require transcription) was unaffected. 
These findings indicate that transcription is essential for IGF-1-induced MET activation. 
 
MET inhibition abrogates IGF-1-induced migration 
Upon activation, MET signaling plays a critical role in prostate cancer cell invasive 
growth (scattering, migration, invasion and metastasis) [34, 35]. I therefore determined if 
IGF-1-induced MET activation affected cellular migration. These experiments were 
performed with a PC3 cell line stably expressing shRNA to c-met, constructed as described 
in Materials and Methods. Expression of the c-met-specific shRNA resulted in >95% 
reduction of MET protein expression compared to PC3 cells expressing a non-targeting 
shRNA (Fig.16A). A migration assay was then performed with cells expressing MET or in 
cells in which MET had been knocked down and migrated cells were counted. Under these 
conditions, IGF-1 induced a 2.5 fold increase in migration in cells expressing a non-targeting 
vector relative to non-stimulated cells (p<0.0001), (Fig. 16B), in agreement with data 
previously published from other groups [114]. In contrast, in cells in which MET was 
decreased by expression of shRNA, no induction of migration by IGF-1 was observed (Fig. 
16B). In cells not stimulated with IGF-1 but in which HGF was used as a chemoattractant, a 
3 fold increase in migration was observed (p<0.0001), consistent with the role of activated 
MET in promoting migration (Fig. 16C).  These results suggest that IGF-1-mediated 
increased migration is mediated by MET activation. Overall, the experiments confirm that 
delayed phosphorylation of MET leads to a functional MET capable of inducing one of its 
principal roles, migration. 
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 Figure 16 - Role of MET in IGF-1-mediated migration of PC3 cells  
Stable knockdown of MET expression by achieved by using an shRNA construct (A). Effects 
of IGF-1 (B) and HGF (C) on migration of PC3 cells were determined.  5x104 Cells were 
plated on top of a Boyden Chamber as described in Materials and Methods. IGF-1 
(100ng/ml) (B) or HGF (15ng/ml) (C) were used as a chemoattractant. Migration was 
compared in shc-Met knockdown cells and respective controls. Data represent Mean and 
SEM from three independent experiments; *p<0.0001 (one-way ANOVA analysis of 
variance). 
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 MET is Activated in Multiple Cell Lines Expressing IGF-1R  
I next examined whether IGF-1-induced MET activation occurred in another 
commonly used metastatic prostate cancer cell line, DU145, which expresses both IGF-1R 
and MET. As before, analysis of MET expression and phosphorylation was performed after 
0h, 18h and 24h of IGF-1 treatment. Kinetics of MET phosphorylation in these DU145 cells 
were similar to that of PC3 (Fig. 17).  Finally, as IGF-1 is abundantly expressed in the serum 
of patients with other types of cancer, I examined the effect of IGF-1 on HT29 colon cancer 
cells and A549 lung cancer cells, both of which express IGF-1R and MET to differing levels. 
Delayed phosphorylation of MET was observed in both of these cell lines (Fig 18A, B), 
though not to the extent of the prostate cancer cells that express higher basal levels of MET. 
These results suggest that delayed activation of MET is likely a common cross talk pathway 
in cells expressing both IGF-1R and MET, and this process may contribute to phenotypes 
associated with MET activation in multiple types of cancer. 
 
Integrins do not mediate cross talk between IGF-1R and MET 
While several mechanisms might contribute to non-ligand mediated MET 
phosphorylation, integrins are an attractive possibility as increased integrin clustering and 
activation not only leads to MET activation, but also to that of Src and downstream pathways 
[115, 116]. To examine this possibility, PC3 cells with stable expression of an Shβ1integrin 
were stimulated with IGF-1. MET was phosphorylated in both non-targeting and shβ1 
integrin knock down cells, suggesting that β1 integrin is not required for delayed MET 
activation (Fig 19). 
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Figure 17 - Effects of IGF-1 on MET phosphorylation in DU145 cells  
DU145 (Prostate Cancer cells) expressing both IGF-1R and MET were stimulated with IGF-
1 (100 ng/ml) as described in Materials and Methods. Expression and phosphorylation of 
MET and IGF-1R examined 18 and 24h later. 
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Figure 18 - Effects of IGF-1 on MET phosphorylation in different cancer cell lines  
HT29 (Colon Cancer) (A) and A549 (Lung Cancer) (B) cell lines, expressing both IGF-1R 
and MET were stimulated with IGF-1 and expression and phosphorylation of MET and IGF-
1R was examined 18h and 24h later. 
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Figure 19 - Effect of integrin β1 knockdown on MET phosphorylation  
IGF-1 (100 ng/ml) was added to non-targeting cells (PC3Shcontrol) or cells that had stable 
knock down of integrin β1 (PC3ShIntβ1) and MET phosphorylation (and expression) was 
determined 24hr later. 
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Discussion 
In this chapter, I demonstrate for the first time that in tumor cell lines in which both 
IGF-1R and MET are expressed, IGF-1R activation is sufficient to lead to a delayed 
phosphorylation of MET in a process that is independent of MET ligand, HGF and without 
increasing MET expression. Phosphorylation of MET occurs at each tyrosine examined, 
suggesting that MET becomes fully activated, in accord with the results demonstrating 
requirement of MET for IGF-1-mediated migration. IGF-1R and Src are required to induce 
delayed MET phosphorylation in a mechanism dependent on transcription since inhibiting 
transcription abolished IGF-1-induced MET activation. The transcriptional mediator/s 
involved in this pathway remains to be identified. It is possible that Src activation facilitates 
the transcription of an unknown factor by enhancing activity of a transcriptional factor and 
the transcription of this unknown factor then leads to MET activation. The results from this 
chapter demonstrate an alternate mechanism of MET activation suggesting that MET re-
activation through receptor cross talk might be one of the reasons for failure of MET 
inhibitors in clinical trials. These findings suggest utilization of another strategy to inhibit 
aberrantly expressed tyrosine kinases in cancer by inhibiting the protein expression of these 
kinases. One such strategy is through miRNA-mediated gene regulation and inhibition of 
multiple targets implicated in cancer progression, which I further examined in the next 
chapters. 
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Chapter 4 
Effects of miR-34a Overexpression on Expression of Targets and 
Properties Associated with Metastasis in vitro 
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MicroRNA-mediated gene regulation and development of miRNA-based therapies for 
therapeutics is one approach to inhibit expression of multiple oncogenic proteins and thereby 
inhibit several cancer-promoting pathways. In prostate cancer, increased expression of 
receptor tyrosine kinases MET and Axl is reported with disease progression, further 
enhancing tumor growth at the metastatic site, principally the bone [40, 48]. Both of these 
receptor tyrosine kinases promote cancer cell survival, proliferation, migration and invasion 
[4, 35, 46, 47, 117]. Aberrant expression of transcription factor c-Myc is reported in prostate 
cancer and evidence from transgenic models implicates c-Myc in driving development of 
invasive prostatic carcinomas [25, 26, 51]. Myc is a proto-oncogene that regulates 
transcription of genes involved in promoting cancer cell growth and proliferation [50]. As 
discussed in Introduction (Chapter 1), targeting multiple gene products is important to inhibit 
activation of disparate signaling pathways that promote cancer progression. MicroRNA-34a 
is a tumor suppressive miRNA that targets and inhibits many of the genes involved in cancer 
development and metastasis. Importantly, miR-34a inhibits protein expression of MET, Axl 
and c-Myc in several cancers [45, 53, 75, 83, 84]. I therefore hypothesized that decreased 
miR-34a expression leads to upregulation of targets that promote PCa progression, and in 
vitro overexpression of miR-34a will inhibit tumor-promoting properties. To test this 
hypothesis, I determined miR-34a expression in prostate cancer cell lines and studied the 
effects of modulating miR-34a expression on biological properties associated with increased 
metastatic potential.  
 
 
 
 
 
66 
Expression of miR-34 family members in PCa cell lines 
To examine the role of miR-34 family in prostate cancer, I used qPCR to quantify 
relative expression of miR-34 family members: miR-34a, miR-34b and miR-34c in PCa cell 
lines. I compared the expression of these miRs in LNCaP cells (which do not metastasize in 
immunocompromised mice) and C42B4 (with low metastatic potential) cells to more 
aggressive PC3 (high metastatic potential) and PC3MM2 (selected for increased metastatic 
potential relative to parental PC3). Expression of miR-34b (Fig. 20A) and miR-34c (Fig. 
20B) was very low in all the tested PCa cell lines. In contrast, expression of miR-34a was 
high in cells of low metastatic potential and decreased substantially in cells of high metastatic 
potential (Fig. 20C). Specifically, expression of miR-34a was decreased by 8-fold in PC3 
and by 12-fold in PC3MM2 compared to C42B4 and LNCaP cells (Fig. 20). This result 
demonstrates that miR-34a expression is inversely proportional to aggressiveness and 
metastatic potential of PCa cell lines, in agreement with a potential role as a tumor 
suppressor in PCa. Among the miR-34 family, I thus chose miR-34a to determine if it 
regulated targets critical to PCa progression, and biological properties associated with 
increased metastasis potential in vitro. 
 
miR-34a targets are overexpressed in aggressive PCa cells 
To examine whether miR-34a overexpression could regulate targets associated with 
increased metastatic potential of PCa cell lines, I determined the expression of MET, Axl and 
c-Myc in LNCap, C42B4, PC3 and PC3MM2 cells. These targets are increased in mRNA 
(Fig. 21A-C) and protein expression (Fig. 21D) in PC3MM2 and PC3 cells relative to 
LNCaP and C42B4 cells, in accord with the different metastatic potentials described above. 
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 Figure 20 – Expression of miR-34 family members in PCa cell lines 
Total RNA was isolated from cell lines and qPCR performed for miR-34b (A), miR-34c (B) 
and miR-34a (C) using TaqMan assays as described in Materials and Methods. U6 was used 
as endogenous control and ΔCt method was used for quantification. Data represents Mean 
and SD from three independent experiments. 
B A 
C 
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Figure 21 - miR-34a targets are overexpressed in aggressive PCa cell lines  
Total RNA and protein was isolated from cell lines and mRNA expression of c-Met (A), c-
Myc (B) and Axl (C) was measured using SYBR Green qPCR using 18S RNA expression as 
endogenous control. Data represents Mean and SD from three independent experiments. 
Protein expression was measured by immunoblotting (D). GAPDH was used as loading 
control. 
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To determine if miR-34a regulated expression of these targets, I overexpressed miR-34a by 
transiently transfecting low miR-34a expressing PC3 and PC3MM2 cells with negative 
control miRNA (N.C.) or miRNA-34a (miR-34a) mimics as described in Materials and 
Methods. Overexpression of miR-34a (Fig. 22A) led to decreased expression of protein (Fig. 
22B) as well as mRNA (Fig. 23) of MET, Axl, and c-Myc in PC3 and PC3MM2 cells. These 
data thus demonstrate that miR-34a overexpression simultaneously inhibits the expression of 
these targets in PCa cell models commonly used to study tumor progression and metastasis. 
 
Effects of miR-34a overexpression on properties associated with aggressiveness and 
metastatic potential of PC3 cell line 
I next determined the biological effects of miR-34a overexpression in PC3 cells. Cells 
transfected with N.C. or miR-34a for 24h were seeded on Boyden chamber inserts as 
described in Materials and Methods. Overexpression of miR-34a significantly decreased the 
ability of PC3 cells to migrate by 50% (Fig. 24A) and the ability to invade by 75% (Fig. 
24B). I then determined the effects of miR-34a on cell proliferation by using a MTS assay. 
Cells after 24h of N.C. or miR-34a were counted and seeded in 96-well plates. Absorbance at 
490nm was measured for different time points by EnVision® multilabel plate reader. 
Overexpression of miR-34a decreased cell proliferation by 1.6-fold at 72 hours and by 2-fold 
at 96 hours compared to N.C. (Fig. 25A). I next performed cell cycle analysis using 
propidium iodide (PI) at various times after N.C. or miR-34a transfection in PC3 cells. A 4-
fold decrease in S-phase was observed beginning at 48 hour, which is maintained through 96 
hours post-transfection (Fig. 25B). After 72 hours, the sub- G1 phase increased by 1.5 fold in 
miR-34a overexpressing cells, reaching a maximum of 2-fold at 96 hours relative to N.C. 
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Figure 22 - Overexpression of miR-34a decreases protein expression of its targets 
miR-34a expression after transient transfection was measured and plotted by using the 
TaqMan assay for miR-34a and U6 as a control (A). Protein expression of miR-34a targets 
(MET, Axl and c-MYC) after N.C. or miR-34a transfection is shown by immunoblotting (B). 
GAPDH was used as loading control.  
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Figure 23 - Overexpression of miR-34a decreases mRNA expression of its targets 
mRNA expression of c-Met (A), Axl (B) and c-Myc (C) after miR-34a overexpression are 
quantified using SYBR Green qPCR in PC3 and PC3MM2 cell lines. * denotes p value <0.05 
as measured by student’s t test.  
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Figure 24 - Effects of miR-34a overexpression on migration and invasion abilities of 
PC3 cells 
Migratory (A) and invasive (B) ability of PC3 was measured after N.C. or miR-34a 
transfection by using Boyden chamber inserts in serum free media. Cells that migrated or 
invaded the matrigel layer were stained, quantified and plotted. * denotes p value <0.05 as 
measured by student’s t test. 
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Figure 25 - Effects of miR-34a overexpression on cell proliferation and cell cycle 
MTS assay was performed on N.C. or miR-34a transfected for different time points and mean 
absorbance at 490 nm from triplicate wells was plotted (A). Propidium iodide staining was 
used for cell cycle analysis and the different cell cycle phases from N.C. or miR-34a 
transfected cells for 48h, 72h and 96h were analyzed and quantified (B). * denotes p value 
<0.05 as measured by student’s t test. 
A 
B 
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transfected cells (Fig. 25B). These results demonstrate that overexpression of miR-34a both 
decreased cell proliferation and increased cell death. To determine what type(s) of cell death 
were occurring, I used a GFP-Certified® Apoptosis/Necrosis detection kit as described in the 
Materials and Methods. An increase in early (AnnVEnzoGold+/7AAD-) and late apoptotic 
(AnnVEnzoGold+/7AAD+) cell populations were observed at 72 and 96 hours post miR-34a 
transfection compared to N.C. transfected cells (Fig. 26A). In addition, an increase in cleaved 
caspase 3 were observed with miR-34a overexpression at 72 and 96 hours (Fig. 26B) 
demonstrating that apoptosis occurred at these time points.  
 
These results thus demonstrate that overexpression of miR-34a decreases properties 
associated with metastasis by inducing apoptosis, decreasing cell proliferation, cell migration 
and invasion, in accord with miR-34a being a tumor suppressive miRNA. Overexpression of 
miR-34a decreases both mRNA and protein expression of MET, Axl and c-Myc, targets 
implicated in prostate cancer progression further corroborating the application of miR-34a 
delivery as a treatment strategy for metastatic prostate cancer which I tested in next the 
chapter. 
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Figure 26 - miR-34a overexpression increases apoptosis in PC3 cells 
Apoptotic cells and necrotic cells in N.C. or miR-34a transfected cells for different time 
points were analyzed and quantified by Gallios FACS using a GFP-Certified® 
Apoptosis/Necrosis detection kit as described in Materials and Methods (A). Protein 
expression of Cleaved Caspase 3 is visualized by immunoblotting after time course 
transfection with N.C. or miR-34a (B). 
A 
B 
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Chapter 5 
Chitosan Nanoparticle Mediated Delivery of miR-34a Decreases Prostate 
Tumor Growth in in vivo Models 
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Most deaths of prostate cancer patients are due to development of bone metastasis. Currently 
available therapies have severe toxicities and limited success in treatment of bone metastasis. 
It is thus essential to develop alternate treatment strategies such as miRNA replacement 
therapy to deliver tumor suppressive miRNA/s that will inhibit multiple genes that contribute 
to growth to cancer progression and growth at metastatic site. Previous studies have 
demonstrated that delivery of tumor suppressive miRNAs in different in vivo cancer models 
is effective in inhibiting primary tumor growth and experimental metastasis [118]. Delivery 
of miR-34a has been shown to be effective in inhibiting growth of orthotopic prostate tumor 
and lung metastasis [84]. However, it is not known whether miR-34a delivery will decrease 
prostate tumor growth in the bone, the principal site of PCa metastasis. In this chapter, I 
determined whether miR-34a could be delivered in in vivo model systems, inhibit its known 
targets and decrease tumor growth. I used PC3MM2-LG cells as they have been shown 
previously to grow in the bone. I used chitosan nanoparticles, currently in development for 
clinical applications due to their favorable biocompatible properties making them an 
attractive delivery vehicle [70, 119]. Previous studies demonstrated effective siRNA and 
miRNA delivery using chitosan nanoparticles in in vivo models without severe toxicities [70, 
73] further corroborating their clinical application. 
 
 miR-34a delivery by chitosan nanoparticles inhibits prostate tumor growth in sub-
cutaneous model 
 I first tested whether delivery of miR-34a in chitosan nanoparticles would lead to 
downregulation of the targets I examined, MET, Axl and c-Myc in in vivo model system. For 
these studies, tumors were grown subcutaneously as described in Materials and Methods and 
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miR-34a was delivered to these tumors systemically encapsulated in chitosan, a cationic, 
biodegradable, naturally occurring polymer [70, 119]. I first determined whether miR-34a in 
chitosan nanoparticles could be delivered systemically and whether its delivery inhibited 
known targets and decreased tumor growth in a sub-cutaneous model. PC3MM2 cells were 
injected in nude mice and one week after tumor injection, intra-venous (i.v.) treatment was 
started to deliver miRNAs encapsulated in chitosan (CH) nanoparticles for control miR or 
miR-34a and continued for two weeks. Robust expression of miR-34a expression was 
observed in tumors that received miR-34a-CH nanoparticles as visualized by ISH (Fig. 27A). 
Next, I examined the expression of MET, Axl and c-Myc. Expression of these proteins was 
decreased as determined by IHC (Fig. 27A, B) and immunoblotting (Fig. 27C) in miR-34a 
treated tumors. Tumor volume measurements demonstrated that miR-34a delivery decreased 
tumor growth compared to control tumors (Fig. 28). The delivery of miR-34a also induced 
apoptosis as measured by an increase in TUNEL positive cells in miR-34a treated tumors 
(Fig. 29) compared to control tumors. This result suggests that miR-34a delivery decreases 
tumor growth by inducing apoptosis.  
 
Effects of miR34a delivery on growth of PCa cells in the bone  
The main question I wished to address was whether systemic miR-34a delivery 
affected tumor growth in an intra-femur model to represent PCa bone metastasis, as no 
effective therapies for bone metastases currently exist. First, to determine whether chitosan 
could deliver small RNAs to the bone, I used Cy5.5-labeled siRNA to detect Cy5.5 
fluorescent signal from the femurs by ex vivo imaging. PC3MM2-LG cells were 
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 Figure 27 - Chitosan mediated delivery of miR-34a decreases target expression 
FFPE slides were stained with H&E and in situ hybridization was performed for miR-34a 
and endogenous control U6 along with IHC for MET and Axl (A). The mean intensities for 
10 areas from each slide at 10x magnification was quantified using color deconvulation H 
DAB macros in ImageJ software or mean intensities were measured with NIS Elements 
software (B). Protein expression of MET, Axl and c-Myc from control and miR-34a treated 
tumors were analyzed by immunoblotting (C) * denotes p value <0.05 as measured by 
student’s t test.  
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Figure 28 - Systemic miR-34a delivery by chitosan nanoparticles decreases sub-
cutaneous prostate tumor growth 
Tumor volume of sub-cutaneous PC3MM2 tumors was measured by caliper and plotted for 
control and miR-34a treated group. * denotes p value <0.05 as measured by student’s t test. 
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Figure 29 - miR-34a delivery induces apoptosis in sub-cutaneous model 
TUNEL staining was performed on tumors as described in Materials and Methods. TUNEL 
positive (Green) cells were quantified using ImageJ software from 10 fields per tumor and 
the mean and standard deviation is plotted and a representative image is shown for control 
and miR-34a treated tumor for nuclear DAPI (blue) and CD31 (red) staining. * denotes p 
value <0.05 as measured by student’s t test. 
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 injected in the femur of nude mice and ten days after tumor injection, unlabeled control or 
Cy5.5-siRNA in chitosan nanoparticles were delivered by tail-vein administration. Animals 
were sacrificed three days after delivery and IVIS 200 visualized fluorescent intensities from 
harvested legs. Fluorescence imaging demonstrates an increase in Cy5.5-siRNA signal 
intensity in the femur with tumor than in the femur without tumor (Fig. 30) suggesting that 
tumor retains the siRNA delivered by chitosan nanoparticle.   
I next determined the effect of miR-34a delivery on established tumors in the femur 
to best mimic treatment of men presenting with bone metastasis. For this experiment, 
PC3MM2-LG cells were injected in the femur of nude mice and bioluminescent activity and 
MRI was used to measure tumor growth and volume. After ten days, when tumors were 
evident in the femurs (as measured by MRI), mice were randomized and treated with either 
control-miR-CH or miR-34a-CH nanoparticles every three days for three weeks through i.v. 
administration. The delivery of miR-34a decreased growth of established prostate tumors in 
the bone compared to control (Fig. 31) as measured by bioluminescent activity of PC3MM2-
LG cells. This finding is supported by decreased tumor volume in miR-34a treated group 
compared to control group as measured by MRI (Fig. 32). PC3MM2 cells cause lytic 
reaction in the bone and miR-34a delivery preserved bone integrity as visualized by micro 
CT analysis (Fig. 33). This study thus demonstrates that miR-34a can be delivered to the 
bone and its delivery decreases tumor growth as well as preserves bone integrity in an intra-
femur mouse model representative of PCa bone metastasis.  
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Figure 30 - Chitosan delivers Cy5.5-siRNA to the femur 
Control or Cy5.5-labeled siRNAs were encapsulated in chitosan nanoparticles and injected 
i.v. and fluorescent imaging performed as describe in Materials and Methods. Both Femurs 
(with and without tumor growing) were harvested and subjected to ex vivo imaging. Red 
arrow indicates fluorescent signal from Cy5.5-siRNA. 
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Figure 31 - Systemic miR-34a delivery by chitosan nanoparticles decreases prostate 
tumor growth in the bone 
Bioluminescent activity from the femur was measured using IVIS 200 and plotted for control 
and miR-34a treatment groups (n=5) and *denotes p<0.05 as measured by student’s t test.   
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Figure 32 - miR-34a delivery decreases prostate tumor volume in the bone 
Tumor volume was measured before and after miR-34a delivery by MRI and plotted (top). 
Representative images from the MRIs of the femurs (red dotted line) for control-CH and 
miR-34a-CH treated mice are shown (bottom). *denotes p<0.05 as measured by student’s t 
test.   
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Figure 33 - miR-34a delivery preserves bone integrity 
micro CT images for control and miR-34a treated mice are shown and red arrow indicates 
bone lesions. 
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Discussion 
Results presented in this chapter providence evidence for miR-34a delivery as a 
strategy to decrease growth of established tumors in the bone with preservation of bone 
integrity. The delivery of miR-34a in an intra-femoral model demonstrates stronger tumor 
inhibition than the sub-cutaneous model. Krzeszinski et al. recently demonstrated that miR-
34a delivery decreased tumor growth primarily by inhibiting osteoclast activity in breast 
cancer and melanoma mouse model [74]. Liu et al. demonstrated that miR-34a delivery 
decreases prostate tumor growth in an orthotopic model [84]. These findings combined with 
my previous results demonstrating anti-tumor effects of miR-34a suggest that miR-34a could 
be affecting both tumor as well as the microenvironment and further corroborates miR-34a 
delivery strategy for treatment of primary and metastatic prostate cancer. The effects of miR-
34a on inducing apoptosis in vivo are much more profound than inducing apoptosis in vitro, 
implicating that additional cell death mechanism/s might be mediated by miR-34a.  
Autophagy, a cellular stress induced survival mechanism has complex role in cancer 
with several studies reporting autophagy-mediated tumor suppression and demonstrating 
involvement of autophagy in promoting cancer cell death [96, 97, 99, 120, 121]. Thus, with 
the goal to address whether autophagy mediates cell death in vitro, in the next chapter I 
determined the effects of miR-34a overexpression on inducing autophagy in cell line models. 
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Chapter 6 
Overexpression of miR-34a Induces Autophagy  
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Autophagy is a process important in maintaining cellular homeostasis by removing damaged 
organelles and proteins from the cell [92]. In cancer, autophagy is induced in response to 
stress conditions for example, nutrient and growth factor starvation, hypoxia and 
chemotherapy [92, 96]. Autophagy can be tumor promoting by enhancing cancer cell 
survival; however, many reports suggest tumor suppressive role of autophagy by regulating 
various cell death pathways including apoptosis [121]. There is evidence of cross talk 
between the apoptosis and autophagy pathways and both processes have been reported to 
occur simultaneously in cancer cells [121]. Downregulation of MET or Axl, two of miR-34a 
targets studied in this dissertation have both been shown to induce both apoptosis and 
autophagy in several cell lines [105, 106]. My observations of cell morphology with bright 
field microscopy indicated changes in cell size and structure occurred over time following 
miR-34a overexpression in PC3 cells (Fig. 34). Specifically, cells overexpressing miR-34a 
appeared are more flattened and larger than N.C. transfected cells starting at 48 hours. By 96 
hours, miR-34a overexpressing cells had a morphology characteristic of cells undergoing 
autophagy. Since, miR-34a downregulates both MET and Axl, in this chapter, I examined 
whether miR-34a overexpression induces autophagy in addition to apoptosis first in PCa cell 
lines, and then determined whether miR-34a overexpression caused similar effects in cell 
lines derived from other tumor types.  
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Figure 34 - miR-34a overexpression alters PC3 cell morphology 
PC3 cells transfected with N.C. or miR-34a at different time points were imaged by bright 
field microscopy at 10X magnification using Nikon camera and representative images are 
shown. 
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Overexpression of miR-34a induces autophagy in cancer cell lines 
Several markers indicative of autophagic process were examined in this chapter. I 
first analyzed Beclin-1 expression in cells transfected with N.C. or miR-34a, as it is involved 
in vesicle nucleation and autophagosome formation [122]. An increase in Beclin-1 protein 
but not mRNA expression (not shown) was observed at 48 hours in miR-34a cells, and 
continues throughout the time course examined (Fig. 35A).  
Next, as a classic marker of autophagy, conversion of LC3I to LC3II, involved in 
autophagosome maturation [123, 124], was examined. LC3II expression was increased in 
miR-34a-overexpressing cells 48 hours after transfection and is maintained at 72, and 96 
hours (Fig. 35A). Next, to quantitatively measure the presence of acidic vesicular organelles 
(AVOs), cells transfected with N.C. or miR-34a for increasing times were stained with 
acridine orange and analyzed by flow cytometry as described in Materials and Methods. An 
increase in acridine orange-positive cells (AO+) was observed in miR-34a overexpressing 
cells at 48 hours with further increases noted at 72 and 96 hours (Fig. 35B), a time frame 
similar to that observed for LC3II increase. To determine whether autophagic structures were 
present in miR-34a overexpressing cells, transmission electron microscopy (TEM) was 
performed. As shown in Fig. 36, miR-34a led to an abundant accumulation of 
autophagosome (AP)-like structures (black arrows) as well as autolysosome (AL)-like 
structures (red arrows) that are not observed in N.C. cells. This result confirms the presence 
and accumulation of autophagic structures in miR-34a-induced autophagy in PC3 cells. 
These data demonstrate that miR-34a overexpression increases molecular markers associated 
with initiation, maturation and progression of autophagy.  
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Figure 35 - miR-34a overexpression induces autophagy in PC3 cells  
Western blots for LC3B, Beclin-1 and GAPDH for N.C. and miR-34a transfected cells for 
different time points are shown (A). Acridine orange staining for N.C. or miR-34a 
transfected cells for different time points was analyzed by Gallios FACS and quantified (B). 
*denotes p<0.05 as measured by student’s t test.  
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Figure 36 - TEM in miR-34a overexpressing PC3 cells 
TEM images at 2500X and 25000X magnification were captured for N.C. and miR-34a 
transfected PC3 cells at 72h. Black arrows indicate autophagosome (AP)-like structures and 
red arrows indicate autolysosome (AL)-like structures.   
N.C. 
miR-34a 
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Overexpression of miR-34a induces autophagy in multiple cell lines 
I next examined whether miR-34a induced autophagy in other PCa cell lines. The 
overexpression of miR-34a increased Beclin-1 expression in PC3MM2 cells and LC3II 
expression in both PC3MM2 and C42B4 cells (Fig. 37A). These increases are similar to 
those observed in PC3 cells. An increase in acridine orange-positive cells is observed in both 
PC3MM2 and C42B4 cells (Fig. 37B) with miR-34a overexpression at 72 hours post-
transfection. To study whether miR-34a-mediated autophagy occurs in other cell types, I 
transfected HepG2 (a hepatocellular carcinoma cell line), A549 (a lung cancer cell line), 
MDA MB 231 (a breast cancer cell line) and SKOV3 (an ovarian cancer cell line) with N.C. 
or miR-34a and measured Beclin-1 and LC3II expression. Overexpression of miR-34a in 
these cell lines increased LC3BII and often Beclin-1 levels at the 72-hour time point, similar 
to what is observed in prostate cell lines (Fig. 38A). Overexpression of miR-34a induced cell 
morphology changes in A549 and HepG2 that are similar to the changes observed in PC3 
cells with increase in cell size and flattened appearance (Fig. 38B). These results suggest that 
miR-34a induces autophagy in PCa and other cancer cell lines examined in this study. 
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Figure 37 - miR-34a induces autophagy in prostate cancer cell lines 
Western blots for Beclin-1, LC3B and GAPDH after 72h transfection with N.C. or miR-34a 
is shown (A). Acridine orange staining quantification (above) and graphs (below) are shown 
at 72h after N.C. or miR-34a transfection (B) in PCa cell lines (PC3, PC3MM2, and C42B4). 
 
 
  
A B 
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Figure 38 - miR-34a induces autophagy in other cancer cell lines 
Western blots for Beclin-1, LC3B and GAPDH after 72h transfection with N.C. or miR-34a 
are shown for cancer cell lines (HepG2, A549, MDA MB231 and SKOV3) (A). Bright field 
images at 10x magnification are shown for A549 and HepG2 at 72h post-transfection with 
N.C. or miR-34a (B) 
  
A549 
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Discussion 
The data presented in this chapter suggest that overexpression of miR-34a induces 
autophagy with increase in LC3II and Beclin-1 expression and increase in acidic vesicular 
organelles (AVOs) as well as increase in autophagic structures (APs and ALs). 
Overexpression of miR-34a induces autophagy in all cancer cell types examined in this 
chapter, suggesting the effects of miR-34a overexpression are not prostate-specific. These 
results are contrary to findings of Liu et al. that suggest that miR-34a inhibits autophagy in 
retinoblastoma cell line by inhibiting HMGB1 under serum starvation and chemotherapy 
conditions [91]. They did not test whether miR-34a inhibits HMGB1 and autophagy in other 
cell types. Expression of HMGB1 at mRNA levels was not affected by miR-34a 
overexpression in PC3 cell line (data not shown), suggesting that HMGB1 was not mediating 
miR-34a induced autophagy in this system. Downregulation of MET or Axl, miR-34a targets 
previously reported to induce autophagy along with apoptosis [105, 106] could be mediating 
miR-34a-induced autophagy observed in this chapter. Also, the levels of miR-34a expression, 
along with different cellular stress conditions could be responsible for autophagy inhibition 
or initiation, since loss of miR-34a-HMGB1 pathway was reported to inhibit autophagy and 
increase ROS production under chemotherapy [91]. In this dissertation, miR-34a expression 
is increased several folds and autophagy occurs under complete growth medium conditions 
which could explain the difference in the result with previously published report. The 
molecular intermediates required for miR-34a-mediated autophagy remains to be identified. 
In the next chapter, I focused on determining whether miR-34a induces canonical autophagy 
by studying the involvement of essential autophagy genes. 
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Chapter 7 
Overexpression of miR-34a Induces a Non-Canonical Form of Autophagy  
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Autophagy is now a general term for defined events that often occur in response to cellular 
stress involved in mediating degradation of damaged cellular components. However, an 
increasing amount of evidence demonstrates that there is not a single pathway that leads to 
“classical” autophagy, rather many forms of autophagy have been reported to affect cell 
growth and proliferation, for example, including an Atg5/Atg7-independent “alternative” 
macroautophagy and Beclin-1-independent autophagy [93, 95, 125]. The proteomic analysis 
of autophagic network in human cells identified a complex network of over 700 interactions 
and more than 400 interacting proteins in this pathway suggesting requirement of different 
intermediates for the diverse forms of autophagy observed in mammalian systems [126]. To 
determine the molecular pathways critical to miR-34a-induced autophagy, in this chapter I 
examined the involvement of key intermediates in the canonical autophagic pathway- Beclin-
1 which is involved in autophagosome formation; ATG5 and ATG7 which are involved in 
autophagosome elongation and completion and ATG4 involved in LC3 processing and 
recycling [96, 122]. I used lentiviral shRNA constructs to knockdown Beclin-1; siRNA 
sequences to knockdown ATG5, ATG7 and ATG4, and doxycline inducible shATG7 PC3 
cells to determine their effects of miR-34a induced autophagy and cell proliferation. 
 
miR-34a-induced autophagy does not rely on Beclin-1 expression 
Since, miR-34a increased Beclin-1 protein expression (chapter 6); I determined 
whether miR-34a-induced autophagy is mediated through Beclin-1. A lentiviral shRNA was 
used to knockdown Beclin-1 in PC3 cells and cells were then FACS sorted for GFP to get 
PC3 shBeclin-1 cells. PC3 and shBeclin-1 cells were then transfected with N.C. or miR-34a 
for 72 hours. Knockdown of Beclin-1 did not change cell morphology, whereas 
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overexpression of miR-34a in shBeclin-1 cells induced similar morphological changes as 
observed in PC3 cells with miR-34a overexpression (Fig. 39). As shown in Fig. 40, protein 
(Fig. 40A) and mRNA (Fig. 41B) expression of Beclin-1 was decreased following lentiviral 
infection, while ATG7 mRNA expression was unaffected (Fig. 41A). These results suggest 
specific knockdown of Beclin-1 was achieved. I next examined the effects of Beclin-1 
knockdown on miR-34a-induced autophagy by determining if conversion of LC3 to LC3II 
occurred. My results demonstrate that miR-34a overexpression increases LC3II expression 
(Fig. 40A lane 1 vs. 2) with or without Beclin-1 knockdown (Fig. 40A, lane 3 vs. 4), 
suggesting that miR-34a induces autophagy independent of Beclin-1.  
To determine if miR-34a still downregulates critical targets in Beclin-1 knockdown 
cells, I examined the expression of its known targets, MET and Axl. As expected, 
overexpression of miR-34a was still effective in inhibiting these targets as shown by decrease 
in MET protein and mRNA expression (Fig. 40 and 41B) and decrease in Axl expression 
(Fig. 41C) in shBeclin-1 cells. I also examined the effects of miR-34a on proliferation in 
Beclin-1 knockdown cells and consistent with my previous data, miR-34a overexpression 
decreased cell proliferation compared to N.C. (Fig. 42, column 1 vs. 2). Beclin-1 knockdown 
also decreased cell proliferation compared to N.C. (Fig. 42, column 1 vs. 3); however, miR-
34a overexpression further decreased proliferation in shBeclin-1 cells (Fig. 42 column 3 vs. 
4). Analysis of acridine orange positive (AO+) cells demonstrated an increase in AO+ cells 
with miR-34a overexpression, irrespective of Beclin-1 knockdown (Fig. 43A). Additionally, 
cell cycle analysis demonstrated a 5-fold increase in the sub G1 fraction of cells following 
miR-34a overexpression in both control and shBeclin-1 cells (Fig. 44B).  
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Figure 39 - Morphology of miR-34a overexpressing PC3 cells with Beclin-1 knockdown 
PC3 and PC3 cells with shBeclin-1 were transfected with N.C. or miR-34a for 72h and bright 
field microscopy was used to capture images at 10x magnification using Nikon camera.  
  
PC3 PC3 shBeclin-1 
N.C. 
miR-34a 
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Figure 40 - Beclin-1 knockdown in PC3 cells 
Western blot for Beclin-1, LC3B, MET and GAPDH are shown for PC3 and PC3 shBeclin-1 
cells with N.C. or miR-34a transfection (A). mRNA expression was measured using SYBR 
Green qPCR and plotted for Beclin-1 (B). * denotes p<0.05 as measured by t test.
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Figure 41 – mRNA expression analysis with Beclin-1 knockdown in PC3 cells 
mRNA expression for ATG7, c-Met and Axl (A-C) was measured using SYBR Green qPCR 
in PC3 and shBeclin-1 cells transfected with N.C. or miR-34a. * denotes p<0.05 as measured 
by student’s t test.  
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Figure 42 - Effects of miR-34a overexpression on proliferation in shBeclin-1 cells 
Hoechst proliferation assay at different time points for PC3 and PC3 shBeclin-1 with N.C. or 
miR-34a transfection is graphed. * denotes p<0.05 as measured by t test.  
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Figure 43 - Acridine Orange and cell cycle analysis in PC3 cells with Beclin-1 
knockdown and miR-34a overexpression 
Acridine orange positive cells were quantified by Gallios FACS and plotted (A) at 72 hours 
post N.C. or miR-34a transfection. Propidium iodide was used for cell cycle analysis at 72 
hours post N.C. or miR-34a transfection and different phases are plotted (B). * denotes 
p<0.05 as measured by student’s t test.  
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These data suggest that miR-34a-induced effects on autophagy, cell proliferation, and 
apoptosis are mediated in a Beclin-1-independent manner. 
 
miR-34a induces ATG5/7-independent autophagy  
I next determined whether ATG5 and ATG7, canonically involved in autophagosome 
elongation and completion [122] were required for the form of autophagy observed upon 
miR-34a overexpression. I used two sequences of siRNA to robustly knockdown ATG5 and 
ATG7 expression in PC3 cells and then transfected them with N.C. or miR-34a. Success of 
knockdown was determined by immunoblotting and qPCR. ATG5 and ATG7 were reduced 
more than 90% at the protein (Fig. 44A and Fig. 45A) and mRNA (Fig. 44B and Fig. 45B) 
levels by corresponding siRNAs. The mRNA expression of ATG7 in siATG5 (Fig. 44C) and 
ATG5 in siATG7 (Fig. 45C) cells is unaffected, suggesting specificity of knockdown of the 
targeted gene. Knockdown of ATG5 and ATG7 did not change cell morphology whereas 
overexpression of miR-34a in siATG5 and siATG7 cells induced similar morphological 
changes as observed in PC3 cells with miR-34a overexpression (Fig. 46 and Fig. 47). As 
expected, siATG5 and siATG7 decreased LC3II levels compared to N.C. (Fig. 44A and 
45A, lane 1 vs. lane 3 and lane 1 vs. 5) confirming that knocking down these gene products 
inhibits basal autophagy. I then examined the effects of miR-34a overexpression on 
autophagy when either ATG5 or ATG7 is reduced by siRNA knockdown. As observed 
previously with PC3 cells, miR-34a overexpression increased conversion of LC3 to LC3II as 
indicated by increase in LC3II band compared to N.C. (Fig. 44A and 45A lane 1 vs. 2).  
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Figure 44 - Effects of ATG5 knockdown in PC3 cells 
Western blots for N.C., miR-34a and two siATG5 sequences with N.C. or miR-34a 
transfection for ATG5, LC3B and GAPDH are shown (A). mRNA expression for ATG5, 
ATG7, c-Met and Axl for N.C., miR-34a and two siATG5 sequences with N.C. or miR-34a 
transfection after 72h was measured by SYBR Green qPCR and plotted. * denotes p<0.05 as 
measured by t test.  
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Figure 45 - Effects of ATG7 knockdown in PC3 cells 
Western blots for N.C., miR-34a and two siATG7 sequences with N.C. or miR-34a 
transfection for ATG7, LC3B and GAPDH are shown (A). mRNA expression for ATG7, 
ATG5, c-Met and Axl for N.C., miR-34a and two siATG7 sequences with N.C. or miR-34a 
transfection after 72h was measured by SYBR Green qPCR and plotted. * denotes p<0.05 as 
measured by t test. 
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Figure 46 - Morphology of miR-34a overexpressing PC3 cells with ATG5 knockdown 
PC3 and PC3 cells with siRNA sequences of ATG5 were transfected with N.C. or miR-34a 
for 72h and bright field microscopy was used to capture images at 10x magnification using 
Nikon camera.  
N.C. miR-34a 
PC3 
siATG5 #4
siATG5 #5
 
 
110 
 Figure 47 - Morphology of miR-34a overexpressing PC3 cells with ATG7 knockdown 
PC3 and PC3 cells with siRNA sequences of ATG7 were transfected with N.C. or miR-34a 
for 72h and bright field microscopy was used to capture images at 10x magnification using 
Nikon camera. 
N.C. miR-34a 
PC3 
siATG7 #2 
siATG7 #3 
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Surprisingly, in the cells in which either ATG5 or ATG7 is reduced, miR-34a overexpression 
still increased LC3II levels compared to N.C. (Fig. 44A and 46A, lane 3 vs. 4 and lane 5 vs. 
6). This result suggests that miR-34a-induced autophagy is independent of ATG5 and ATG7. 
Interestingly, miR-34a overexpression itself was sufficient to decrease ATG5 protein (Fig. 
44A lane 1 vs. 2), further suggesting that ATG5 is not involved miR-34a-mediated 
autophagy. Both c-met (Fig. 44D and 46D) and Axl (Fig. 44E and 45E) mRNA levels were 
decreased with miR-34a overexpression in siATG5 and siATG7 cells, demonstrating miR-
34a still downregulates these targets that are involved in mediating autophagy [105, 106]  
To determine the effects of miR-34a on proliferation in cells with reduced ATG5 and 
ATG7, a Hoechst proliferation assay was performed. Overexpression of miR-34a decreases 
proliferation compared to N.C. (Fig. 48A and 48B column 1 vs. 2), consistent with my 
previous data. Reduced ATG5 and ATG7 expression decreased basal autophagy and cell 
proliferation compared to N.C. (Fig. 48A and 48B column 3 and 4 vs. column 1) consistent 
with previous reports [107]. However, miR-34a overexpression further decreased 
proliferation in cells with reduced ATG5 (Fig. 48A column 3 vs. 4 and 5 vs. 6) and ATG7 
(Fig. 48B column 3 vs. 4 and 5 vs. 6). This result suggests that ATG5 and ATG7 affect 
canonical autophagy and cell proliferation, but not miR-34a-induced autophagy and its effect 
on cell proliferation. 
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Figure 48 - Cell Proliferation in siATG5 and siATG7 cells with miR-34a overexpression 
Hoechst proliferation assay at different time points for N.C., miR-34a and two siATG5 (A) 
and two siATG7 (B) sequences with N.C. or miR-34a transfection is graphed. * denotes 
p<0.05 as measured by student’s t test. 
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To minimize potential effects due to transient transfection, I also examined PC3 cells 
with doxycycline-inducible shATG7 to assess the effects of miR-34a overexpression when 
ATG7 is stably reduced. Upon addition of doxycycline, ATG7 protein (Fig. 49A) and mRNA 
(Fig. 49B) are decreased without affecting ATG5 mRNA levels (Fig. 51A), confirming the 
inducible knockdown of ATG7. Overexpression of miR-34a in the absence or presence of 
doxycycline (in which shATG7 was induced) led to similar morphologic alterations observed 
by miR-34a transfection alone; changes similar to that observed in PC3 and siATG7 cells 
with mR-34a overexpression (Fig. 50). As a control, miR-34a overexpression still decreased 
mRNA levels of c-Met (Fig. 51B) and Axl (Fig. 51C) in both non-induced and shATG7 
conditions. To examine the effects of shATG7 on miR-34a-induced autophagy, I determined 
LC3II protein expression. Consistent with my results in PC3 transiently transfected with 
siATG7, an increase in LC3II expression was observed with miR-34a overexpression in both 
non-induced (Fig. 49A) and Dox-induced shATG7 (Fig. 49A lane 3 vs. 4) cells. This result 
supports the previous data that miR-34a effects on LC3II are independent of decreased 
ATG7 expression. Further, a decrease in cell proliferation was observed in non-induced cells 
with miR-34a overexpression (Fig. 52 column 1 vs. 2). Similar to results obtained with 
siATG7, shATG7 decreased proliferation compared to N.C. at 96 hours (Fig. 52 column 1 
vs. 3) and miR-34a overexpression further decreases proliferation in cells with reduced 
ATG7 at 96 hours (Fig. 52 column 3 vs. 4). Taken together, these data suggest that miR-34a 
overexpression induces autophagy that is independent of decreased ATG5 and ATG7 
expression. 
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Figure 49 - Effects of miR-34a overexpression in doxycycline inducible shATG7 PC3 
cells 
Western blots for ATG7, LC3B and GAPDH (A) and mRNA expression for ATG7 (B) in 
non-induced and Dox-induced shATG7 cells transfected with N.C. or miR-34a is plotted * 
denotes p<0.05 as measured by student’s t test. 
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 Figure 50 - Morphology of miR-34a overexpressing in doxycycline inducible shATG7 
PC3 cells 
Non-induced and doxycycline-induced shATG7 PC3 cells with were transfected with N.C. or 
miR-34a for 72h and bright field microscopy was used to capture images at 10x 
magnification using Nikon camera.  
N.C. miR-34a 
PC3 shATG7 
no Dox 
PC3 shATG7 
+ Dox 
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Figure 51 – mRNA expression analysis with miR-34a overexpression in doxycycline 
inducible shATG7 PC3 cells 
mRNA expression for ATG5, c-Met and Axl was measured in non-induced and Dox-induced 
shATG7 cells transfected with N.C. or miR-34a * denotes p<0.05 as measured by student’s t 
test.  
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Figure 52 - Cell Proliferation in doxycycline inducible shATG7 PC3 cells 
Hoechst proliferation assay at different time points for PC3 shATG7 no Dox and +Dox with 
N.C. or miR-34a transfection is graphed. * denotes p value <0.05 as measured by student’s t 
test. 
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ATG4 knockdown effects autophagy independent of miR-34a overexpression 
Since, knockdown of ATG7 and ATG5, the intermediates involved in the 
downstream processing of LC3II did not affect the form of autophagy induced by miR-34a 
overexpression; I examined whether ATG4, a cysteine protease involved upstream in the 
conversion of pro-LC3 to LC3I is required for miR-34a induced autophagy. ATG4 has four 
isoforms, ATG4A, ATG4B, ATG4C and ATG4D with overlapping and distinct functions. I 
used siRNA sequences to knock down all four isoforms of ATG4 in PC3 cells and then 
transfected the cells with either control (N.C.) or miR-34a mimics for 72 hours. The 
overexpression of miR-34a in PC3 cells led to altered cellular morphology that was similar to 
that observed with previous knockdowns or by overexpression of miR-34a alone; however, 
knockdown of ATG4 alone induced morphological changes with cells appearing larger and 
flattened (Fig. 53) compared to control cells. Overexpression of miR-34a in siATG4 cells 
further altered the morphology of the cells with increases in cell size and  in the perinuclear 
region (Fig. 53). Next, I prepared protein lysates and performed immunoblotting for different 
ATG4 isoforms. All isoforms of ATG4 (A-D) were reduced with siRNA sequences 
confirming that the knockdown was efficient in decreasing ATG4 expression (Fig. 54A). 
LC3II expression was increased with miR-34a overexpression compared to N.C. cells. 
However, knockdown of ATG4 alone increased LC3II expression, while the overexpression 
of miR-34a in siATG4 cells further increased LC3II expression (Fig. 54A). This result 
suggests that knockdown of ATG4 itself has effects on increasing LC3II levels, independent 
of autophagy induced by miR-34a. Cell cycle analysis demonstrated increases in the sub G1 
fraction of cells and decrease in S-phase following miR-34a overexpression in both control 
and siATG4 cells (Fig. 54B).  
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Figure 53 - Morphology of PC3 cells with ATG4 knockdown and miR-34a 
overexpression  
PC3 cells were transfected with control siRNA or ATG4 siRNAs and then after 24 hours, 
transfected again with N.C. or miR-34a mimics and bright field images were taken with 
Nikon digital camera.  
siControl 
siATG4 
N.C. miR-34a 
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Figure 54 - Effects of ATG4 knockdown in PC3 cells 
PC3 cells were transfected with control siRNA or ATG4 siRNAs and then after 24 hours, 
transfected again with N.C. or miR-34a mimics. After 72 hours of miRNA transfection, cells 
were harvested for protein for immunoblotting with ATG4 antibodies (ATG4A, 4B, 4C and 
4D) and LC3B (A); for cell cycle analysis with PI (B) and for acridine orange FACS analysis 
(C). 
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Analysis of acridine orange positive (AO+) cells demonstrated an increase in AO+ cells with 
miR-34a overexpression (Fig. 54C), while ATG4 knockdown itself increased AO+ cells and 
miR-34a overexpression further increased AO+ cells with ATG4 knockdown (Fig. 54C). 
Confocal imaging with AO to visualize the acidic vesicular organelles further corroborated 
the FACS results with increased accumulation of acridine orange in cytoplasm with miR-34a 
overexpression compared to control (Fig. 55, top panel). ATG4 knockdown also increased 
cytoplasmic acridine orange staining similar to FACS results and overexpression of miR-34a 
further increased AO stained acidic vesicular organelles in ATG4 knockdown cells (Fig. 55, 
bottom panel). These results suggest that ATG4 knockdown has effects on impaired 
autophagy with increased accumulation of LC3II and acridine orange positive cells 
independent of miR-34a and overexpression of miR-34a can induce autophagy even with 
ATG4 knockdown. 
 
Discussion 
Results from chapters 6 and 7 provide definitive evidence that overexpression of 
miR-34a induces autophagy, with both molecular markers (e.g., increase in lipidation of LC3 
to form LC3II, increase in acidic vesicular organelles) and morphologic criteria (presence of 
autophagosomes and autolysosomes by TEM) occurring (Figures 35-38, 40, 44-45 and 49). 
However, as discussed in the Introduction, recent studies demonstrate that molecular 
pathways leading to autophagy are diverse, suggesting there may not be a single “canonical” 
pathway. In this chapter, I demonstrate that the form of autophagy induced with miR-34a 
overexpression does not rely on the expression of Beclin-1, ATG5 or ATG7, whose gene 
products “classically” play essential roles in mediating autophagy following nutrient  
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Figure 55 - Acridine Orange staining in PC3 cells with ATG4 knockdown and miR-34a 
overexpression 
PC3 cells were transfected with control siRNA or ATG4 siRNAs and then after 24 hours, 
transfected again with N.C. or miR-34a mimics. After 72 hours of miRNA transfection, 
acridine orange was added for an hour and cells were fixed with 4% paraformaldehyde and 
sucrose solution. Fixed cells were then imaged with confocal microscope at 20X 
magnification. 
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starvation, metabolic stress or by chemotherapeutic agents [92, 124] though possible effects 
of incomplete knockdown cannot be excluded. ATG4 knockdown has effects on autophagy 
independent of miR-34a overexpression.  
My results with ATG5 and ATG7 agree with those of Nishida et al., who first 
reported an Atg5/Atg7-independent “alternative” macroautophagy in which autophagosomes 
and autolysosomes were still observed in mouse cells with Atg5 or Atg7 knockout [95]. 
However, lipidation of LC3 to form LC3II did not occur in this alternative autophagy 
observed in their Atg5-/- or Atg7-/- MEF cells [95]. Thus, autophagy I observe has some of the 
characteristics of being ATG5/ATG7 independent; however robust increase in LC3II 
expression in both siRNA and shRNA mediated knockdown of ATG5 and ATG7 
respectively, suggest that additional molecular intermediates may play a role in promoting 
this “non-canonical” autophagy.  
Since, miR-34a overexpression increased Beclin-1 protein expression, I expected 
Beclin-1 knockdown to inhibit miR-34a-induced autophagy. Surprisingly, miR-34a still 
increased LC3II expression in shBeclin-1 cells similar to what was observed in control PC3 
cells overexpressing miR-34a. ATG4 is involved in LC3 processing and recycling. A recent 
study in CML demonstrated that ATG4B is a direct target of miR-34a and is overexpressed 
in CML [144]. Knockdown of ATG4B led to increase in LC3II and p62 indicative of 
impaired autophagy [144]. I did not observe decrease of ATG4B protein levels with miR-34a 
overexpression suggesting that it might not be a target of miR-34a in this system. My results 
with the knockdown of all four isoforms of ATG4 increased LC3II with increased 
accumulation of acidic vesicular organelles as determined by acridine orange staining 
suggesting that ATG4 knockdown could have separate effects on autophagy that are different 
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from miR-34a-mediated-autophagy. These results suggest that the form of autophagy 
induced with miR-34a requires different intermediates than those involved during the 
canonical autophagy. 
Either Axl or MET inhibition is known to induce autophagy in diverse tumor cell 
lines [105, 106]. These studies however, did not demonstrate whether canonical or non-
canonical form of autophagy was induced upon Axl or MET inhibition. My results 
demonstrate that overexpression of miR-34a still inhibited MET and Axl expression even in 
Beclin-1 or ATG5/ATG7 knockdown cells suggesting that downregulation of these targets 
could be involved in miR-34a-mediated autophagy. Inhibition of autophagy genes studied in 
this chapter decreased cell proliferation; however overexpression of miR-34a causes further 
decrease in proliferation in Beclin-1 or ATG5/ATG7 knockdown cells. These results 
implicate a role of miR-34a-mediated autophagy in decreasing cell proliferation either alone 
or in combination with apoptosis that needs to be further examined.  
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Chapter 8 
Expression of miR-34a in Human Prostate Cancer Samples 
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In this dissertation, I have determined that miR-34a is downregulated in metastatic prostate 
cancer cell lines and its delivery in in vivo models is effective in decreasing tumor growth. 
Overexpression of miR-34a can induce non-canonical form of autophagy in cell line models. 
The relationship between miR-34a expression and autophagy in prostate cancer clinical 
samples is not known. Also, data supporting inverse correlation of miR-34a expression with 
disease aggressiveness suggests a trend toward decreased miR-34a expression with 
increasing Gleason score [89]. Previous studies using publically available datasets or qPCR 
for miR-34a expression have reported decreased miR-34a in prostate cancer with further 
decreases in expression with PCa progression [89, 127]. However, methods used in these 
studies show large variations in miR-34a expression providing no visualization of expression 
in different cell types. In this chapter, I determined miR-34a expression in human prostate 
cancer samples by in situ hybridization that allowed for direct visualization of miR-34a 
expression in normal prostate cells vs. prostate cancer tissue. Tissue microarrays (TMAs) 
from different stages and grades of PCa provide a large cohort of clinical specimens that can 
be stained with miR-34a and quantified to determine whether there is inverse correlation in 
miR-34a expression with progressive PCa.  
 
Expression of miR-34a is decreased in human prostate cancer specimens 
To examine miR-34a expression in human prostate gland and cancer tissue, I received 
human PCa samples from the Department of GU Medical oncology. H&E and in situ 
hybridization (ISH) was performed on these samples that allowed visualization of 
heterogeneity and tissue-specific identification of miR-34a expression. Similar areas from 
H&E and ISH slides were imaged. High expression of miR-34a is observed in the normal 
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prostate gland, with expression almost exclusively in the basal cell layer (Fig. 56A and 56E, 
inset, 56B and 56F, inset) while the luminal cells do not stain for miR-34a in the normal 
gland (Fig. 56A and 56E, inset, 56B and 56F, inset). In the tissue in which normal prostate 
gland and adjoining prostate cancer are present (Fig. 56C and 56D), miR-34a expression is 
lost in the cancerous tissue (Fig. 56G and 56H). This result suggests that there is a decreased 
miR-34a expression in human PCa samples.  
 
Results from a small sample set suggest that miR-34a expression is decreased in 
prostate cancer compared to normal gland. More samples would be required to do miR-34a 
staining and quantification of expression to determine whether miR-34a expression decreases 
with disease progression. In situ hybridization demonstrates that miR-34a has differential 
expression in basal vs. luminal cells of the prostate gland. As discussed in Introduction 
(Chapter 1), it has been demonstrated that PCa can arise from both luminal and basal cells in 
Pten-null mouse model and there is evidence of basal to luminal cell differentiation [12]. It 
remains to be determined whether loss of miR-34a occurs in prostate cancer arising from 
basal cells and whether re-expression of miR-34a in luminal cells will inhibit cancer 
development. Loss of miR-34a could be one of the mechanisms of aberrant activation c-Myc 
that can promote cancer initiation. It will be the focus of future studies to determine the 
expression of miR-34a targets in different prostate cell types and in cancer tissue. This study 
highlights the further need to understand the regulation of miR-34a expression in prostate 
gland for better understanding of its role in cancer initiation and development. 
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Figure 56 - miR-34a is downregulated in PCa 
The expression of miR-34a was measured by in situ hybridization. Similar areas for H&E 
(A-D) and miR-34a ISH (E-H) were captured and are shown above. 
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Chapter 9 
Discussion 
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When organ-confined, prostate cancer is curable. However, when prostate cancer 
metastasizes, most frequently to the bone, it is almost always lethal. Despite newly approved 
FDA therapies that prolong survival, increased lifespan for men with metastatic PCa is 
relatively minimal. The failure of therapies could be attributed to development of de novo 
resistance mediated by interactions with the microenvironment or acquired resistance 
mediated by alterations in the tumor cell that promote tumor growth. It is thus essential to 
develop novel strategies for treatment of advanced disease, which will require a better 
understanding of PCa progression and tumor growth in the bone.  
In this dissertation, I have focused on understanding several aspects of prostate cancer 
biology related to regulation of specific tyrosine kinases that play a role in PCa progression 
and targeting multiple gene products associated with metastatic disease. The thesis raised 
issues with respect to targeting individual molecules, demonstrated the promise of using 
miRNA-mediated strategies to target multiple molecules and revealed the complicated inter-
related biologic consequences of this targeting, apoptosis and autophagy.  
  
Activation of IGF-1/1R pathway induces ligand-independent delayed MET activation 
In cancer, several growth factor receptors and receptor tyrosine kinases are aberrantly 
expressed contributing to tumor development and progression [128, 129]. One mechanism of 
receptor activation is mediated through binding of its ligand and activation of downstream 
signaling pathway [130]. However, recent studies have identified ligand-independent 
receptor cross talk mechanisms in cancer. There are numerous mechanisms by which this 
occurs, including amplification of non-targeted receptor with overlapping functions, 
activation of a non-targeted receptor, or reactivation of a targeted receptor [41, 43, 131]. A 
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well-studied example is crosstalk between EGFR and MET. EGFR activation has been 
demonstrated to lead to delayed MET activation in non-small cell lung cancer cell lines [43], 
MET is amplified after erlotinib or gefinitib treatment in lung tumors [42, 132]. Thus, to 
understand which therapies might be effective in combination and/or how to best use targeted 
therapies, cross talk mechanisms need to be better understood. A theoretical publication 
[133] suggested specific classes of receptors that perform overlapping functions and are 
likely to be activated upon inhibition of a targeted kinase. Biologically, my goal was to 
determine if kinases known to be activated and have targeted inhibitors in clinical trial would 
lead to cross talk that might explain the lack of success of some of these trials. In prostate 
cancer and in PCa bone metastasis, IGF-1R and MET receptors are overexpressed and 
predict poor prognosis [36, 40, 112, 113, 134, 135]. Multiple inhibitors to both of these 
signaling axes are in clinical trials [113, 136]. These trails have generally led to failure, both 
through development of resistance and re-activation of targets. Thus, to determine whether 
re-activation of targeted kinase occurs through cross talk with other receptors, I studied IGF-
1R mediated MET activation in Chapter 3 of this dissertation. I demonstrated that in cell 
lines that express both IGF-1R and MET receptor tyrosine kinases, activation of IGF-1R by 
IGF-1 induces delayed phosphorylation of MET which is independent of its ligand, HGF. 
This implies that in cancers where both receptors are present on cancer cells, presence of 
IGF-1 in the tumor microenvironment can lead to MET phosphorylation. 
It was next important to determine if the phosphorylation led to activated MET 
functions and further, to examine if IGF-1R biologic functions were mediated through MET. 
Activation of IGF-1/1R and MET pathway was biologically functional as determined by 
phosphorylation of catalytic tyrosine sites on MET indicative of full MET activation and also 
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demonstrated by activation of downstream Akt, Src and MAPK signaling pathways. 
Activation and expression of IGF-1R was essential for IGF-1 to phosphorylate MET as in the 
absence of IGF-1R this delayed MET activation was abolished. This result is similar to 
findings of Dulak et al. on cross talk between EGFR and MET, where they demonstrate that 
activation of EGFR by EGF leads to MET activation [43]. However, unlike their result, MET 
expression did not increase upon IGF-1 stimulation.  
Dasatinib (a multi-targeted pan Src family kinase inhibitor)-mediated inhibition of 
Src phosphorylation diminished both IGF-mediated (Chapter 3) and EGF-mediated-MET 
[43] activation, demonstrating that activated Src serves as the central regulator of atleast 
several receptor cross talk mechanisms. In line with this observation, constitutive activation 
of Src was sufficient to induce MET phosphorylation even in the absence of IGF-1. 
However, in this study it was not determined whether Src directly mediates MET activation. I 
speculate that activation of Src enhances the activity of a transcription factor that then 
induces transcription of unknown protein/s that interact with MET and trigger its 
phosphorylation either directly or indirectly through other adaptor or MET-binding partner/s. 
The results from treatment of cells with pan-transcription inhibitor actinomycin D that 
abolished IGF-1 induced MET phosphorylation further corroborates the role of 
transcriptional component/s in mediating IGF-1/1R induced MET activation. Dulak, et al. 
also implicate transcriptional involvement of unknown factor/s in mediating growth factor 
cross talk with EGF and MET [43]. It will be the focus of future studies to determine if 
common transcription factors are involved in cross talk among receptors, and then identify 
MET binding proteins in the complex that could be involved in mediating IGF-1/1R to MET 
activation, as IGF-1R does not directly lead to MET phosphorylation. These results are 
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summarized in the model of IGF-1/1R induced MET phosphorylation that requires Src 
activation and unknown transcriptional mediators and further leads to activation of 
downstream signaling pathways including migration (Fig. 57).  
Though several mechanisms for ligand independent MET activation including 
upregulation of plexins, G-coupled receptors, integrin binding, have been reported, I 
investigated whether integrins are involved in inducing delayed MET phosphorylation, as 
β1integrins interact with MET, and are themselves known to be important in PCa bone 
metastasis  [137] and have been implicated in MET activation [41]. For these experiments, I 
determined whether cross talk between IGF-1R and MET still occurred in integrin β1 
knockdown cells (PC3 cells). However, knockdown of integrin β1did not inhibit IGF-1-
induced MET phosphorylation suggesting integrin β1 was not involved. It remains to be 
investigated whether other integrins for example, integrin β3 implicated in prostate cancer 
progression  [138] could be a mediator in IGF-1/1R-induced MET activation. I did not study 
bi-directional IGF-1/1R activation upon HGF stimulation and this will be another area for 
exploration to further understand receptor cross talk mechanism. 
In summary, this study adds to previous works suggesting combinatorial targeting of 
multiple tyrosine kinases as a better therapeutic approach in cancers where more than one 
kinase is activated. MET activation through ligand-independent mechanisms in different 
cancers indicates that MET activation might serve as a converging node required by other 
kinases to mediate their biological effects. This is highlighted in my study where MET 
knockdown abolishes IGF-1-induced migration. 
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Figure 57 - Model of Ligand Independent MET activation by IGF-1/1R pathway 
This figure illustrates that activation of IGF-1R by IGF-1 increases MET phosphorylation but 
not its expression and does not require MET ligand, HGF but requires Src activation and 
transcription (bold arrows) through an unidentified factor X. 
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 Taken together, these findings implicate that cross talk mechanism between receptor 
tyrosine kinases might be responsible for failure of small molecule ATP inhibitors against 
targeted-kinases. There could be common transcription-mediated pathways involving 
unidentified transcription factors and proteins/kinases that activate more than one RTK and 
understanding these pathways as well as identifying the common transcription factor might 
be one approach to targeting multiple kinases. These findings further implicate that targeting 
multiple aberrantly expressed kinases through strategies that not only inhibit their activation 
but also their expression might be more important in cancer therapeutics. 
 
miR-34a is decreased in metastatic PCa cell lines and its delivery decreases prostate 
tumor growth 
The above study had several implications, as described, but led to questions such as, 
elimination of cross talk through downregulation of an activated receptor; and are in line with 
the seeming necessity for inhibiting multiple targets for better therapeutic efficacy. Thus, 
delivery of tumor suppressive miRNAs, which downregulate the expression of multiple 
targets is now an emerging approach with therapeutic promise. In Chapters 4 and 5 of this 
dissertation, I focused on miR-34a, a miRNA downregulated in many cancers and considered 
a tumor suppressive miRNA since it targets many oncogenic proteins. Specifically, this 
miRNA was chosen in prostate cancers as it downregulates MET, thus extending my 
previous work, miR-34a also downregulates Axl, an emerging target for advanced-stage PCa 
and c-Myc, an important oncogene de-repressed at earlier stages of PCa, and has additional 
targets not assessed in this thesis, such as, Bcl-2, Notch1, cyclin D1, CDK4, CDK6, etc. 
which may augment apoptosis and cell cycle arrest [75, 139]. Increased expression of MET, 
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Axl and Myc has been reported in primary and advanced PCa [25, 38, 40, 46-48, 51, 117] as 
discussed in Introduction (Chapter 1) section. In the last few years, targeting MET activation 
is an attractive area of research in pre-clinical and clinical studies. However, MET inhibitors 
have limited success and are associated with severe toxic effects in clinical trials [4]. 
Recently, the dual VEGFR2 and MET small molecule inhibitor, Cabozatinib failed to 
demonstrate statistical significance in prolonging overall survival (OS) in Phase III clinical 
trial of men with mCRPC. Axl inhibitors have just entered phase 1 clinical trial [140] and 
have not been tested for use with advanced PCa. c-Myc being a transcription factor is not 
considered as a “druggable” target and targeting Myc-dependent synthetic lethal interactions 
is being further explored [54]. This presents a need for a therapeutic strategy that will inhibit 
multiple targets promoting growth and progression in prostate cancer. Importantly, miR-34a 
inhibited all three targets in vitro and in vivo in PCa as shown in Chapter 4 and 5 results, 
making it a useful candidate for potentially inhibiting tumor growth in bones. These data is in 
agreement with previous reports examining these targets in breast, non-small cell lung, 
colorectal, and prostate cancer [45, 53, 82-85, 87], although none of these targets have been 
examined simultaneously before my studies. Thus, miR-34a was a potential candidate for 
replacement therapy that would inhibit prostate tumor growth in the bone. 
The first issue to be addressed was the relationship between miR-34a expression and 
aggressiveness and metastatic potential of well-characterized tumor cell lines. My in vitro 
data demonstrated that miR-34a expression decreases with aggressiveness and metastatic 
potential of PCa cell lines. I further demonstrated that miR-34a effects properties associated 
with metastasis including decrease in migration, invasion, proliferation; cell cycle changes 
and increase in apoptosis, demonstrating direct anti-tumor effects. Although other groups 
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have shown that miR-34a induces senescence [141], I did not observe senescence upon miR-
34a overexpression by using SA-β-galactosidase assay (data not shown).  
During the course of my studies, the attractiveness of this approach became obviously 
popular, as many studies in miR-34a in prostate and other cancers have appeared since my 
work was initiated. But several unanswered questions still remained, including whether 
delivery of miR-34a would affect growth of bone metastasis, which as noted many times in 
this thesis is the major killer from prostate cancer. To address the effects of miR-34a delivery 
on tumor growth in the bone I used an intra-femoral mouse model for my therapeutic 
experiment and demonstrated that miR-34a delivery through chitosan nanoparticles 
decreased tumor growth. Due to lack of current animal models for PCa that lead to 
spontaneous bone metastasis, I used direct injection of tumor cells in the femur to best 
represent PCa bone metastasis. This is the first study to demonstrate a therapeutic benefit of 
miR-34a in the treatment of established prostate tumors in the bone. Although Liu et al. used 
miR-34a delivery for orthotopic PC3 tumors in mice [84], my study provides evidence to 
support miR-34a delivery in advanced PCa as well. Krzeszinski et al. recently showed that 
delivery of miR-34a decreases bone metastases of breast cancer and melanoma cell line in 
intra-cardiac mouse model by inhibiting osteoclast activity [74]. They used genetic and 
pharmacologic model to demonstrate that decreased bone metastasis was due to altered 
expression of miR-34a in the bone microenvironment, providing convincing evidence that, 
for these models, that primary effectiveness was due to a single protein in osteoclasts, Tgif2, 
and emphasizes the importance of targeting the tumor microenvironment [74].  However, 
therapies in osteoblastic PCa bone metastasis that target primarily microenvironment, as 
determined in part, by their failure to reduce PSA and tumor remaining in bone scans, such as 
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cabozatinib and Rad 223 [4, 60] suggest that targeting microenvironment in PCa bone 
metastases is insufficient to have prolonged efficacy and overall survival. Thus, the goal 
from the beginning of my studies was to attempt to target tumor cells. My findings along 
with those of Krzeszinski, et al suggest that miR-34a can be useful in targeting both the 
tumor as well as the microenvironment, and may account for growth inhibition in bone that 
exceeded the tumor reduction in sub-cutaneous studies. A potential role of Tgif2 inhibition in 
prostate cancer bone metastasis models would be an interesting subject of future work.  
In previous studies, delivery of downregulated miRNAs has been shown to inhibit 
tumor growth in different in vivo models without any severe toxic effects [68, 75, 85, 86, 88]. 
Likewise, in my study, I observed that delivery of miR-34a led to inhibition of tumor growth 
without any toxic effects in the mice. Since, no current therapies are effective in treating PCa 
metastatic to bone without severe toxicities; this study presents an alternative treatment 
strategy to circumvent this problem. A more detailed understanding of the biology resulting 
from this strategy will be required if miR-34a delivery is to become therapeutically relevant.  
This dissertation did not address the mechanism of miR-34a downregulation in PCa, 
which can be explored in future research. Previous studies have reported that miR-34a is 
regulated by p53-dependent and p53-independent mechanisms [79, 80, 139]. p53 is mutated 
in PC3 and PC3MM2 cells, indicating that loss of p53 might be involved in miR-34a 
downregulation in these cell lines [84]. However, since p53 mutations are not as common in 
PCa (>20%) and generally occur at later stages [6, 142], other mechanisms including 
hypermethylation of miR-34a promoter are very likely be responsible for downregulation of 
its expression, given the frequency of miR-34a decreases I observed in human specimens. 
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My results from in vivo studies demonstrate stronger induction of apoptosis by miR-34a 
delivery compared to miR-34a overexpression in vitro, which increased apoptosis by 20-
30%. Downregulation of miR-34a targets, MET and Axl, studied in this dissertation have led 
to increase in apoptosis and autophagy leading to decrease in cell viability [105, 106]. This 
led me to speculate whether autophagy along with apoptosis could be involved in miR-34a 
overexpression mediated decrease in cancer cell growth. 
 
Overexpression of miR-34a induces non-canonical form of autophagy 
A major part of my thesis focused on autophagy, for several reasons. As discussed 
above, knockdown of either MET or Axl in different systems has been shown to induce 
autophagy. Further, overexpression of miR-34a induced morphological characteristics, 
including increases in cell size and with transmission electron microscopy, autophagosomes 
and autolysosomes were detected upon miR-34a overexpression. As autophagy has received 
considerable attention both for its role in cellular survival and potentially promoting 
tumorigenesis, as well as its role in cellular death and tumor suppression, understanding 
whether autophagy occurred and by what mechanism became important to my work. 
Prolonged treatment with targeted molecular therapy induces autophagy leading to cell death 
[97] and treatment with chemotherapeutic agent, Rottlerin induces autophagy associated with 
cell death in different cancer cell lines [99, 120], further emphasizing the complex biological 
effects of autophagy in cancer models. Since, my studies involved prolonged miR-34a 
treatment, with miR-34a delivered every three days in in vivo studies and the overexpression 
in vitro was over a time course of four days, it was important to assess whether autophagy 
was induced in my system.  
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 The goal of my work with miR-34a-induced autophagy was to determine whether 
autophagy inhibited or augmented miR-34a therapeutic effects. To do this it was important to 
first inhibit autophagy and then use miR-34a overexpression to determine its effects on cell 
proliferation and autophagy marker, LC3II expression. I used bafilomycin A1 that inhibits 
late stage autophagy by preventing fusion between autophagosomes and lysosomes. 
However, bafilomycin is a toxic chemical with other cellular targets that led to more than 
90% cell death in PC3 cells (data not shown). To overcome the toxicities of chemical 
inhibitors, I used knockdown of genes involved in the autophagy pathway to inhibit 
autophagy and then overexpress miR-34a. Knockdown of Beclin-1, ATG5, ATG7 and ATG4 
was not very toxic to the cells and effective in inhibiting basal autophagy. However miR-34a 
overexpression still induced autophagy even with the knockdown of these genes with 
increase in LC3II and decrease in cell proliferation. Thus, implicating that miR-34a did not 
require these genes for mediating its molecular and biological effects.   
Nishida et al. reported an ATG5/ATG7-independent macroautophagy that did not 
increase LC3II expression [95]. Contrary to this finding, my results with miR-34a 
overexpression demonstrate increase in LC3II even in ATG5 and ATG7 knockdown cells. 
Scarlatti, et al. reported that resveratrol (Res) induces Beclin-1-independent non-canonical 
autophagy in breast cancer cells with increase in LC3II upon Res treatment in Beclin-1 
knockdown cells [125]. Similar to this finding, my results in Chapter 7 demonstrate increase 
in LC3II in shBeclin-1 cells with miR-34a overexpression. These data suggest existence of 
compensatory mechanism through other E1 and E3-like enzymes that are involved in 
mediating LC3 conversion upon autophagy induction by miR-34a. Different intermediates 
could be recruited to induce autophagy as Liu et al. demonstrated that miR-34a inhibits 
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autophagy under starvation or chemotherapy that enhances cell death by inhibiting HGMB1 
expression in retinoblastoma cells [91]. This led me to speculate that under conditions of 
serum starvation, miR-34a could inhibit protective autophagy that promotes cell survival 
whereas in complete growth medium conditions, miR-34a overexpression induces a form of 
autophagy that promotes cell death.  
Taken together, these findings further implicate that diverse forms of autophagy are 
induced with different cellular stresses through several intermediates that might lead to 
different biological effects. Identification of key molecular intermediates involved in the 
form of autophagy induced by miR-34a overexpression will be important in delineating the 
mechanism and biological effects of miR-34a-mediated autophagy. ATG4 is a cysteine 
protease that mediates conversion of LC3 to LC3I that is further processed to LC3II, a 
lipidated of  LC3, and is also required in deplidation to LC3I [143]. Knockdown of ATG4 
homologue, ATG4B in chronic myeloid leukemia (CML) leads to impaired autophagy with 
increase in LC3II and decrease in cell viability and cell proliferation [144]. It was further 
demonstrated that miR-34a directly targets and inhibits ATG4B though the effects of miR-
34a on autophagy were not examined [144]. These results suggest that downregulation of 
ATG4B could lead to impaired autophagy. To determine whether ATG4B was targeted by 
miR-34a in my system and could be involved in miR-34a mediated autophagy, I performed 
knockdown of ATG4B and then overexpressed miR-34a to assess the effects on autophagy. 
The other homologues of ATG4 including ATG4A, ATG4C and ATG4D with overlapping 
functions [143] could negate the effects of miR-34a inhibition of ATG4B and thus, I used 
siRNAs to knockdown all four isoforms of ATG4 which led to increased LC3II and acridine 
orange positive cells indicative of autophagy. In my studies, ATG4B or the other isoforms do 
 
 
142 
not appear to be a direct target of miR-34a. Future studies could focus on knockdown of 
individual homologues to examine the involvement of ATG4 isoforms in miR-34a-mediated 
autophagy or their effects on autophagy independent of miR-34a.  
Downregulation of miR-34a targets, Axl and MET can induce autophagy through 
unidentified mechanisms [105, 106]. In this study, I tried to determine at least in part, the 
mechanism of autophagy induced through downregulation of these receptor tyrosine kinases 
by miR-34a. Future work will focus on determining whether downregulation of MET and 
Axl alone or in combination is sufficient to induce the form of autophagy as observed with 
miR-34a overexpression. As summarized in Figure 58, miR-34a could be mediating its 
effects indirectly through inhibition of RTKs, Axl and MET. Other autophagy intermediates 
including Beclin-1, ATG5 and ATG7 are not involved in miR-34a-mediated autophagy while 
ATG4 knockdown itself affects autophagy independent of miR-34a overexpression (Fig. 58). 
There could be other direct targets of miR-34a involved in autophagy induction and it will be 
the focus of future studies to identify direct or indirect modulators of miR-34a-induced 
autophagy. 
This study highlights that miR-34a could have different effects on autophagy in 
different cellular and tumor contexts under different conditions and it will be important to 
determine whether autophagy is induced or inhibited in patients on MRX34 clinical trial, to 
understand the therapeutic effects of miR-34a delivery.  
 
 
 
143 
Figure 56 - Model of miR-34a-induced autophagy 
This figure illustrates that miR-34a overexpression induces apoptosis and a form of 
autophagy that is independent of Beclin-1, ATG5 and ATG7, which are involved in 
conversion of LC3I to LC3II (Blue dotted arrow). Autophagy induced with miR-34a 
overexpression could be through inhibition of RTKs, Axl and MET that can then lead to 
apoptosis, autophagy (Black dotted arrows) and decreased cell proliferation. Alternatively, 
other direct targets of miR-34a could lead to autophagy induction. Downregulation of ATG4 
(red dotted arrow) led to increase in LC3II independent of miR-34a. 
Modified with permission from “Randall-Demello S, Chieppa M and Eri R (2013). Intestinal 
epithelium and autophagy: partners in gut homeostasis. Frontiers in Immunology. Doi 
10.3389/fimmu.2013.00301.”  
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Summary and Future Directions 
In conclusion, in this dissertation I have demonstrated ligand-independent delayed 
MET activation through IGF-1/1R pathway that requires IGF-1R, activated Src and 
transcription. Future studies will focus on identifying the transcriptional intermediate that 
mediates MET phosphorylation by identifying binding proteins in MET complex.  
Clinical and in vitro data implicates an inverse relationship between miR-34a 
expression and prostate cancer progression with decreased in miR-34a expression in 
metastatic prostate cancer cell lines. I further demonstrated that decreased miR-34a 
expression leads to upregulation of targets that promote PCa progression, and in vivo miR-
34a replacement therapy could be a useful treatment for advanced PCa. Overexpression of 
miR-34a induced a form of non-canonical autophagy independent of ATG5, ATG7 and 
Beclin-1 expression. Further studies will focus on examining involvement of other direct 
targets of miR-34a including growth factor receptors in mediating the form of autophagy 
induced by miR-34a.  
I demonstrated that miR-34a delivery could be a therapeutic strategy for PCa bone 
metastasis. It would require more studies with other xenograft models to determine the 
efficacy of miR-34a treatment for clinical applications. Also, it will be important to study 
whether prolonged treatment with miR-34a results in residual tumor resistant to miR-34a 
therapy. It is possible that resistance to miR-34a therapy can arise upon longer treatment 
duration and that will be an area of further exploration. Combination miRNA therapies 
focusing on delivering two or more miRNAs downregulated in cancers can be developed to 
test whether it will be more effective than single miRNA delivery. I studied expression of 
IGF-1 and IGF-1R targeting miR-145 in prostate cancer cell lines (data not shown) as an 
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extension to my current research.  The expression of miR-45 is downregulated in prostate 
cancer cell lines and its overexpression decreased IGF-1 secretion as well as phosphorylation 
of IGF-1R (data not shown). Future studies can determine whether miR-145 modulates IGF-
1/1R signaling and whether dual miRNA delivery of miR-145 and miR-34a to target IGF-
1/1R pathway along with MET, Axl and c-Myc signaling axes in prostate xenograft models 
will be more effective than single miRNA-delivery.  
Inhibition of growth factor receptors could lead to different forms of autophagy as 
demonstrated by downregulation of Axl and MET and antagonism of prolactin receptor [97, 
105, 106] than autophagy mediated by targeting direct intermediates with different biological 
consequences. This work attempted to understand the form of autophagy induced by miR-
34a and whether it was mediated indirectly through downregulation of some of these 
receptors or directly through modulating essential autophagy genes. It can be further 
examined whether single or combined knockdown of Axl and MET is sufficient to induce the 
form of autophagy mediated by miR-34a overexpression. Further, inhibition of apoptosis and 
cell proliferation in the presence and absence of miR-34a will help in defining the biological 
effects of this non-canonical autophagy. Finally, determining the expression of autophagy 
markers and whether miR-34a influences autophagy in patients would be useful in 
understanding the therapeutic applicability of miR-34a delivery strategy for cancer treatment. 
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